



Cite this: *RSC Adv.*, 2019, 9, 28961

Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors

Xiangyi Jiang,^a Gaochan Wu,^a Waleed A. Zalloum,^b Megan E. Meuser,^c Alexej Dick,^c Lin Sun,^a Chin-Ho Chen,^d Dongwei Kang,^a Lanlan Jing,^a Ruifang Jia,^a Simon Cocklin,^{*c} Kuo-Hsiung Lee,^e Xinyong Liu^{*a} and Peng Zhan^{*a}

The HIV-1 capsid (CA) protein plays crucial roles in both early and late stages of the viral life cycle, which has intrigued researchers to target it to develop anti-HIV drugs. Accordingly, in this research, we report the design, synthesis and biological evaluation of a series of novel phenylalanine derivatives as HIV-1 CA protein inhibitors using the Cu(I)-catalyzed azide and alkyne 1,3-dipolar cycloaddition (CuAAC) reaction. Among this series of inhibitors, compound **II-10c** displayed a remarkable anti-HIV activity ($EC_{50} = 2.13 \mu\text{M}$, $CC_{50} > 35.49 \mu\text{M}$). Furthermore, surface plasmon resonance (SPR) binding assays showed that compounds **II-10c** and **PF-74** (lead compound) have similar affinities to HIV-1 CA monomer. Further investigation showed that the weak permeability and water solubility of representative compounds were probably the important factors that restricted their cell-based activity. Preliminary structure–activity relationships (SARs) were inferred based on the activities of these compounds, and their known structure. The most promising new compound was studied with molecular dynamics simulation (MD) to determine the preferred interactions with the drug target. Finally, the activities of members of this series of inhibitors were deeply inspected to find the potential reasons for their anti-HIV-1 activity from various perspectives. This highlights the important factors required to design compounds with improved potency.

Received 29th July 2019
 Accepted 6th September 2019

DOI: 10.1039/c9ra05869a

rsc.li/rsc-advances

1. Introduction

Acquired immunodeficiency syndrome (AIDS) is a severe infectious disease mainly caused by the human immunodeficiency virus type 1 (HIV-1) that undermines the human immune system.^{1,2} Although the use of highly active antiretroviral therapy (HAART) improves the quality and length of life of HIV patients, there currently is no drug or method to eradicate AIDS.³ Therefore, there is still an urgent need for the identification of new anti-HIV drugs with new mechanisms of action to achieve HIV infection cure.^{4,5}

The HIV-1 capsid (CA) protein is essential for HIV-1 replication and plays crucial roles in both early (uncoating, reverse transcription, nuclear import, integration, *etc.*) and late

(assembly and maturation) stages of the viral life cycle.^{6,7} Once the viral core enters the cytoplasm of the host cell, the CA protein interacts with host cell factors such as Cyclophilin protein A (CypA), cleavage and polyadenylation specificity factor-6 (CPSF6), and nucleoporin 153 (NUP153) to promote timely capsid uncoating followed by coordinated reverse transcription, nuclear import of the pre-integration complex, and integration of double-stranded viral DNA into the host genome.^{8–10} In addition, in the late stage of HIV-1 replication, the assembly and maturation of CA protein is essential for the formation and release of infectious virus particles.¹¹ If the formation of CA is inhibited, the viral replication process will be disturbed and the ability to infect host cells will be almost lost.¹² Due to its high sequence conservation (around 70%) and multiple functions in replication, HIV-1 CA protein has become an attractive therapeutic target for anti-HIV drug research.^{13,14}

Due to its importance as an anti-HIV target, several chemotypes of HIV-1 CA protein inhibitors have been found.^{6,15} Among them, compound **PF-74** (Fig. 1a) that has been widely studied as a functional small molecule.¹⁶ **PF-74** is composed of a phenylalanine core (red part, Fig. 1a), an indole ring (pink part, Fig. 1a) and a linker connecting them (blue part, Fig. 1a). Recent research indicates that **PF-74** binds an intermolecular interface which consists of the N-terminal domain (NTD) of one subunit and the C-terminal domain (CTD) of the adjacent subunit in a CA hexamer.^{17–19} The phenylalanine core forms interactions

^aDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012, Ji'nan, Shandong, PR China. E-mail: xinyongl@sdu.edu.cn; zhanpeng1982@sdu.edu.cn; Tel: +86-531-88380270; +86-531-88382005

^bDepartment of Pharmacy, Faculty of Health Science, American University of Madaba, P. O. Box 2882, Amman, 11821, Jordan

^cDepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA. E-mail: sc349@drexel.edu; Tel: +1-215-762-7234

^dDuke University Medical Center, Surgical Oncology Research Facility, Box 2926, Durham, NC, 27710, USA

^eNatural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA. E-mail: khlee@unc.edu; Tel: +1-919-962-0066



with ASN57, ILE73, ALA105, TYR130 and THR107 in the NTD interface; and the methylindole group interacts with ARG173, GLN63, and LYS182 which exist in the CTD interface of the neighboring subunit (Fig. 1b).^{20,21} Preliminary studies of PF-74 showed that capsid destabilization is its main mechanism of action.¹⁴ Further capsid disassembly assays indicated that PF-74 induces viral uncoating.^{22,23} Since PF-74 competes with CPSF6 and NUP153 for the same binding site of the CA protein, it affects multiple processes of the HIV-1 life cycle by interfering with CA-host factor interactions.^{24,25} However, the low inhibitory activity and poor metabolic stability of PF-74, necessitates a further modification to address these issues.^{26,27} Preliminary optimization of PF-74 has been carried out by several research groups, as shown in compounds 1–3 with improved potency (Fig. 1c). Notably, 4-methoxyaniline and 3,5-difluorophenyl were frequently used as substituent groups around the phenylalanine core motif, which significantly improves the activity of the resulting compounds (Fig. 1c).

Inspired by the preliminary efforts, we focused our attention on further optimization of PF-74. Previously, we modified the linker region and indole substituents to obtain a series of phenylalanine derivatives.⁷ The 1,2,3-triazole was used as a linker in the structure to increase the stability and rigidity of compounds (Fig. 1d). Furthermore, the triazole has two H-bond acceptors, which provides potential additional interactions with the surrounding residues through H-bonding, π - π stacking, and dipole interaction.^{28–30} Besides, the application of the Cu(I)-catalyzed azide and alkyne 1,3-dipolar cycloaddition (CuAAC), often referred to as the “click reaction”, makes it convenient to synthesize 1,4-disubstituted triazole.^{31–33} In this study, we continued to design and synthesize 51 other 1,2,3-triazole phenylalanine derivatives divided into three sub-series, to enrich structure–activity relationships (SARs). Specifically, methoxy and fluorine atoms were introduced into the substituent groups of the phenylalanine scaffold. Meanwhile, we replaced the linker with 1,2,3-triazole to obtain the compounds





Fig. 1 The design of novel phenylalanine derivatives as HIV-1 CA inhibitors. (a) Structure of PF-74; (b) the binding mode of PF-74 in the NTD-CTD interface of CA protein hexamer. Yellow dashed lines indicate H-bond interactions. (c) Several reported phenylalanine derivatives as HIV-1 CA protein inhibitors. (d) Target compounds designed in this work.





Scheme 1 Reagents and conditions used to synthesize I-8(a-u). (i) 4-methoxy-*N*-methylaniline, PyBop, DIEA, CH₂Cl₂, r.t., 8–10 h; (ii): CF₃-COOH; CH₂Cl₂, r.t., 5–6 h; (iii) propionic acid, HATU, DIEA, CH₂Cl₂, r.t., 10 h; (vii): azide substituents; CuSO₄·5H₂O, VcNa, THF/H₂O (v : v = 1 : 1), 30–60 °C, 4–6 h.

I-8(a-u). Based on a sub-series I structure, the compounds **II-10(a-o)** were yielded by introducing a benzene ring into the linker. This enabled the indole substituents to act more extensively on the CA protein CTD interface. Subsequently, fluorine atoms on phenylalanine skeleton were removed to obtain sub-series III, which can help further the understanding of the effect of fluorine atoms on the anti-HIV-1 activity.

In the present study, we designed and synthesized 51 phenylalanine derivatives divided into three sub-series, and evaluated their anti-HIV-1 activities. Moreover, we have confirmed that representative compound **II-10c** can act on HIV-1 CA with high specificity using surface plasmon resonance (SPR) binding assays. Molecular dynamics simulation (MD), water solubility and membrane permeability of representative compounds were performed to further understand the activities of these compounds. Results of this research could be used for further rational optimization and discovery of CA-targeting compounds with improved potency and drug-like qualities.

2. Results and discussion

2.1. Chemistry

The synthetic route of phenylalanine derivatives **I-8(a-u)** is illustrated in Scheme 1. (*S*)-2-((*tert*-Butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (**4**) was selected as the starting material, which was reacted with 4-methoxy-*N*-methylaniline to afford the intermediate **5**. After removal of the Boc group, free amino was treated with propionic acid to yield the

key intermediate **7**. Finally, the desired compounds **I-8(a-u)** were obtained by CuAAC reaction between key intermediate **7** and various the azide substituents.


Scheme 2 illustrates the synthesis of compounds **II-10(a-o)**. The intermediate **6** in sub-series I was used as the starting material, which was reacted with 3-ethynylbenzoic acid to afford the intermediate **9**. The desired compounds **II-10(a-o)** were obtained through CuAAC reaction between intermediate **6** and diverse azide substituents.

As depicted in Scheme 3, compounds **III-15(a-o)** were synthesized according to the similar procedures from **II-10(a-o)**. *N*-(*tert*-Butoxycarbonyl)-*L*-phenylalanine (**11**) was reacted with 4-methoxy-*N*-methylaniline, followed by removing the Boc protection to obtain the compound **13**. Then, the resulting intermediate **13** was coupled with 3-ethynylbenzoic acid using HATU and DIEA as catalysts to afford the intermediate **14**. Azide substituents reacted with **14** to produce target compounds **III-15(a-o)** in the presence of Cu(I).

All novel phenylalanine derivatives were characterized by electrospray ionization mass spectrometry (ESI-MS), proton nuclear magnetic resonance (¹H NMR) spectroscopy, and carbon nuclear magnetic resonance (¹³C NMR) spectroscopy. The purity of all target compounds was higher than 95% as confirmed by HPLC analysis.


2.2. Biological activity

The newly synthesized compounds **I-8(a-u)**, **II-10(a-o)** and **III-15(a-o)** were tested *in vitro* for their anti-HIV-1 activity in



Scheme 2 Reagents and conditions used to synthesize II-10(a-o). (i) 3-ethynylbenzoic acid, HATU, DIEA, CH₂Cl₂, r.t., 10 h; (ii): azide substituents; CuSO₄·5H₂O, VcNa, THF/H₂O (v : v = 1 : 1), 30–60 °C, 4–6 h.





Scheme 3 Reagents and conditions used to synthesize III-15(a–o). (i) 4-methoxy-*N*-methylaniline, PyBop, DIEA, CH₂Cl₂, r.t., 8–10 h; (ii) CF₃COOH; CH₂Cl₂, r.t., 5–6 h; (iii) 3-ethynylbenzoic acid, HATU, DIEA, CH₂Cl₂, r.t., 10 h; (vii) azide substituents; CuSO₄·5H₂O, VcNa, THF/H₂O (v : v = 1 : 1), 30–60 °C, 4–6 h.

a multicycle assay using fully infectious HIV-1 NL₄₋₃ virus and TZM-bl cells. During the assay PF-74 was used as a reference compound. The cytotoxicity of these compounds towards TZM-bl cells was evaluated in parallel. The results, expressed as EC₅₀, CC₅₀ and SI (selectivity index, the ratio of CC₅₀/EC₅₀) are illustrated in Tables 1 and 2.

As shown in Table 1, most of the compounds exhibited preferred anti-HIV-1 (TZM-bl cell) activity with micromolar EC₅₀ values ranging from 3.27 μM to 14.76 μM. Among them, two compounds with the most anti-HIV potency were I-8h (EC₅₀ = 3.58 ± 0.64 μM, CC₅₀ > 18.85 μM) and I-8j (EC₅₀ = 3.27 ± 0.78 μM, CC₅₀ > 18.16 μM), however their activity was less potent than that of the lead compound PF-74 (EC₅₀ = 0.28 μM, CC₅₀ > 23.50 μM).

In sub-series I, 21 compounds were synthesized. According to the results of the activity we were able to draw preliminary structure–activity relationship (SAR). In the first subset we varied substitution at the triazole ring keeping the core region unvaried, compounds I-8(a–l) in Table 1. We varied the position of the functional group on the benzene ring substituent, and observed the change of activity. When the substituent is electron donating group (CH₃ or Cl), there does not appear to be any significant difference between the EC₅₀s of these compounds (I-8a/I-8b/I-8c and I-8d/I-8e/I-8f). However, this pattern shows that the electron withdrawal effect (NO₂ or CN) has a different effect on the activity than that of electron donating group (CH₃ or Cl). Specifically, position 3 is the best position for CN (I-8h > I-8i > I-8g). However, NO₂ has a different pattern, where the best activity when it is positioned at position 2 (I-8j > I-8l ≈ I-8k). The analysis proved that benzyl substituents are more sensitive to CA CTD, especially for nitro or cyano groups. Accordingly, the activity is better for the substitution by an electron withdrawing group. Also, it was obvious that different substituents at the same site have significant effects on the activity by comparing I-8a/I-8d/I-8g/I-8j, I-8b/I-8e/I-8h/I-8k and I-8c/I-8f/I-8i/I-8l.

Then, we turned our attention to the SAR of the other target compounds. Unfortunately, compared with substituted benzenes, the activity of compounds containing naphthalene (I-8m/I-8n) or quinoline (I-8o) is extraordinary poor, or even disappears completely. However, the replacement of quinoline with benzo[*d*][1,3]dioxole resulted in a slightly improved antiviral activity toward HIV-1 strains. Besides, the activity of I-8t was more potent than I-8p, I-8r or I-8s. The results showed that

the position and type of hydrogen-bonding donors/acceptors in substituents had a significant effect on anti-HIV-1 activity. Finally, we introduced the structural fragment of zidovudine into the substituent part and obtained the compound I-8u, which lost its anti-HIV-1 activity.

Table 2 illustrates the anti-HIV-1 activity and cytotoxicity of II-10(a–o) and III-15(a–o). Among 30 phenylalanine derivatives, only compounds II-10c, II-10d, II-10e, II-10h, II-10i, III-15d and III-15h exhibited anti-HIV-1 activity at the test concentration. Notably, compound II-10c displayed remarkable anti-HIV activity (EC₅₀ = 2.13 ± 0.75 μM, CC₅₀ > 35.49 μM). Compared to the most active compound I-8j in the sub-series I, its anti-HIV activity increased significantly.

A concise investigation of SARs was summarized as followed. Above all, in some cases, it is beneficial for increasing anti-HIV-1 activity to introduce fluorine atoms on the phenylalanine scaffold by comparing II-10c/III-15c, II-10e/III-15e and II-10i/III-15i. Interestingly, when the substituents targeting the CTD interface are non-aromatic structures, compounds (II-10l/III-15l, II-10m/III-15m and II-10n/III-15n) lost anti-HIV-1 activity completely. This indicates that π–π stacking interactions between the indole fraction of PF-74 and the surrounding residues in the CTD interface has a great influence on the anti-HIV activity. Also, if the nonpolar aromatic rings were introduced in this position, the activities of the resulting compounds (II-10g/III-15g, II-10j/III-15j and II-10k/III-15k) are also relatively poor.

All in all, some useful information was provided by the biological evaluation results and the SAR analysis above will be beneficial to future design of CA protein inhibitors targeting the CTD-NTD interface.

2.3. Binding to HIV-1 CA protein

Surface plasmon resonance (SPR) analysis was employed to quantify the binding interactions of CA-targeting small molecules to HIV-1 CA protein. The most active compound II-10c was selected, as a representative compound for the assay. PF-74 was used as the positive control. The isotherms are shown in Fig. 2.

Fig. 2 shows that PF-74 binds to HIV-1 CA protein firmly, with an equilibrium dissociation constant (*K*_D) values for monomer and hexamer of 2.8 μM and 92.8 nM, respectively. The SPR results also indicate that II-10c (2.20 ± 0.23 μM) binds the CA




Table 1 Anti-HIV-1 activity and cytotoxicity of the novel phenylalanine derivatives I-8(a–u)

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
	 I-8 (a-u)			
I-8a		8.85 ± 2.69	>19.25	>2.18
I-8b		9.43 ± 2.31	>19.25	>2.04
I-8c		10.59 ± 3.46	>19.25	>1.82
I-8d		9.63 ± 2.04	>18.52	>1.92
I-8e		8.33 ± 1.41	>18.52	>2.22
I-8f		8.70 ± 1.65	>18.52	>2.13




Table 1 (Contd.)



Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
I-8g		9.61 ± 2.07	>18.85	>1.96
I-8h		3.58 ± 0.64	>18.85	>5.27
I-8i		5.84 ± 1.53	>18.85	>3.23
I-8j		3.27 ± 0.78	>18.16	>5.55
I-8k		10.00 ± 1.76	NA ^d	ND ^e
I-8l		9.26 ± 2.54	>18.16	>1.96




Table 1 (Contd.)




Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
I-8m		14.76 ± 3.24	>18.00	>1.22
I-8n		14.58 ± 2.34	>18.00	>1.23
I-8o		NA ^d	NA ^d	ND ^e
I-8p		14.19 ± 3.46	>18.20	>1.28
I-8q		9.15 ± 2.80	>18.67	>2.04
I-8r		12.32 ± 2.39	>17.11	>1.39
I-8s		11.12 ± 2.00	>18.23	>1.64
I-8t		4.21 ± 0.90	>17.56	>4.17



Table 1 (Contd.)



I-8 (a-u)

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
I-8u		>15.63	>15.63	ND ^e
PF-74	—	0.28 ± 0.06	>23.50	>83.93

^a EC₅₀: the concentration of the compound required to achieve 50% protection of TZM-bl cells against HIV-1-induced cytopathic effect, as determined by the MTT method. ^b CC₅₀: the concentration of the compound required to reduce the viability of uninfected cells by 50%, as determined by the MTT method. ^c SI: selectivity index, the ratio of CC₅₀/EC₅₀. ^d NA: no anti-HIV-1 activity or cytotoxicity at the test concentration. ^e ND: not determined.

monomer with similar affinity compared to **PF-74** (2.80 ± 1.40 μM). However, **PF-74** prefers to interact with HIV-1 CA hexamer. This could explain **PF-74** increased anti-HIV-1 activity compared to **II-10c**. In conclusion, the SPR analysis found no statistically significant difference between the binding affinities of compound **II-10c** and the lead **PF-74** for HIV-1-CA monomer. Therefore, the novel 1,2,3-triazole phenylalanine derivatives can be defined as classical HIV-1-CA inhibitors.

2.4. Molecular dynamics (MD) simulation

Compound **II-10c** has been chosen for the MD simulation due to its high activity. **II-10c** was docked by Autodock 4.2.6 using default settings in a preparation step for the MD simulation.³⁴ We used the same MD simulation and analysis procedures described in our previously published research to keep consistency of the simulation between different CA HIV-1 monomer inhibitors series.⁷

II-10c, which is the most active compound of this series as CA HIV-1 monomer inhibitors was simulated for 1 μs to explore its interactions with the active site amino acids as well as its binding modes. The root mean square deviation (RMSD) of amino acids during the simulation is plotted in Fig. 3a. The

figure shows that the structure has deviated from the X-ray structure and existed in different conformational ensembles. This shows that the binding of the inhibitor-induced these conformational forms which are also accompanied by different conformations of the inhibitor. Accordingly, the RMSD of **II-10c** was calculated and plotted in Fig. 3b. The figure shows that **II-10c** exists in few conformational forms with most abundant form after 500 ns of the MD simulation.

The entire trajectory underwent cluster analysis based on **II-10c** (no fit) according to the results of RMSD of the protein and the inhibitor, which show that the inhibitor binds with different modes. The clustering analysis retained four different clusters with two being the most populated. Fig. 4a and b show the representative structure interactions of the first (32.7%) and second (30.0%) clusters respectively. The binding of **II-10c** to the CA HIV-1 monomer is different from that of **PF-74**, where the core scaffold is oriented to the outside of the active site.

In the first cluster representative structure the nitro group undergoes electrostatic interactions with LYS70, where the nitro group does not interact with amino acids in the second cluster structure. However, the phenyl ring of the




Table 2 Anti-HIV-1 activity and cytotoxicity of the novel phenylalanine derivatives II-10(a–o) and III-15(a–o)

R₁ = F, II-10 (a-o)
R₁ = H, III-15 (a-o)

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
II-10a		>35.49	>35.49	ND ^e
II-10b		>35.49	>35.49	ND ^e
II-10c		2.13 ± 0.75	>35.49	>16.66
II-10d		23.37 ± 6.88	>32.02	>1.37
II-10e		8.16 ± 2.56	>32.01	>3.92
II-10f		>30.27	>30.27	ND ^e
II-10g		>32.80	>32.80	ND ^e



Table 2 (Contd.)




$R_1 = \text{F}$, II-10 (a-o)

$R_1 = \text{H}$, III-15 (a-o)

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
II-10h		7.48 ± 2.83	>33.24	>4.44
II-10i		21.50 ± 4.53	>32.32	>1.50
II-10j		>31.66	>31.66	ND ^e
II-10k		>31.66	>31.66	ND ^e
II-10l	CH ₃ OC=OCH ₂ -	NA ^d	NA ^d	ND ^e
II-10m	CH ₃ CH ₂ OC=OCH ₂ -	NA ^d	NA ^d	ND ^e
II-10n	CH ₃ OC=O(CH ₂) ₃ -	>33.80	>33.80	ND ^e
II-10o		>27.94	>27.94	ND ^e
III-15a		>33.86	>33.86	ND ^e
III-15b		>33.86	>33.86	ND ^e



Table 2 (Contd.)




$R_1 = F$, II-10 (a-o)

$R_1 = H$, III-15 (a-o)

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
III-15c		>33.86	>33.86	ND ^e
III-15d		26.16 ± 7.30	>33.97	>1.30
III-15e		>33.97	>33.97	ND ^e
III-15f		>32.01	>32.01	ND ^e
III-15g		>34.86	>34.86	ND ^e
III-15h		9.37 ± 3.18	>35.36	>3.77
III-15i		>34.33	>34.33	ND ^e
III-15j		>33.57	>33.57	ND ^e



Table 2 (Contd.)



$R_1 = \text{F}$, **II-10 (a-o)**
 $R_1 = \text{H}$, **III-15 (a-o)**

Compounds	R	EC ₅₀ ^a (μM)	CC ₅₀ ^b (μM)	SI ^c
III-15k		>33.57	>33.57	ND ^e
III-15l	CH ₃ OC=OCH ₂ -	NA ^d	NA ^d	ND ^e
III-15m	CH ₃ CH ₂ OC=OCH ₂ -	NA ^d	NA ^d	ND ^e
III-15n	CH ₃ OC=O(CH ₂) ₃ -	>35.99	>35.99	ND ^e
III-15o		>29.42	>29.42	ND ^e
PF-74	—	0.52 ± 0.18	>47.00	>90.38

^a EC₅₀: the concentration of the compound required to achieve 50% protection of TZM-bl cells against HIV-1-induced cytopathic effect, as determined by the MTT method. ^b CC₅₀: the concentration of the compound required to reduce the viability of uninfected cells by 50%, as determined by the MTT method. ^c SI: selectivity index, the ratio of CC₅₀/EC₅₀. ^d NA: no anti-HIV-1 activity or cytotoxicity at the test concentration. ^e ND: not determined.

nitrobenzene ring in the second structure forms hydrophobic interactions with LYS70, or it could be involved in ion-induced dipole interactions with the positively charged lysine amino acid. The fluorophenyl ring of the core region forms hydrophobic interactions with PRO17 in the first cluster structure, while it is distant for it in the second cluster structure. The methoxyphenyl ring of the core region forms hydrophobic interactions with CYS14 in the second structure, where this ring is distant from CYS17 in the first structure. The methoxy group of the methoxyphenyl ring in the second structure forms aliphatic hydrogen bond with the backbone of ILE15. The methyl group of the core region forms hydrophobic interactions with LEU20 in the second structure. The results of hydrogen bond analysis showed that there is no stable hydrogen bond during the MD

simulation between **II-10c** and the binding site. The results of MD simulation showed that the binding between **II-10c** and CA HIV-1 monomer is not strong in both clusters, which explains the difference in the activities between **PF-74** and **II-10c**.

2.5. Cell permeability

In order to further explore the reason why **II-10c** has similar target affinity but lower anti-HIV-1 activity compared with **PF-74**. The unidirectional cell permeability of compound **II-10c** was studied. As shown in Table 3, cell permeability assays revealed that **II-10c** had poor membrane permeability. More concretely, in experiments carried out with Caco-2 cells, the apparent permeability (P_{app}) of **II-10c** was below $0.1 \times 10^{-7} \text{ cm s}^{-1}$, while






Fig. 2 SPR isotherms of compound II-10c (a) binding to two variants of the CA protein (monomer and disulfide-stabilized hexamer) respectively with PF-74 as the reference (b). Isotherms are an average of 3 replicates with error bars indicating SEM.

reference compounds for low and high permeability, such as nadolol and metoprolol, showed P_{app} values of $0.8 \times 10^{-7} \text{ cm s}^{-1}$ and $1.64 \times 10^{-5} \text{ cm s}^{-1}$, respectively. This suggests that the permeability of the novel designed compounds may weaken the anti-HIV-1 activity at the cellular level.

2.6. Water solubility

Because water solubility and lipid-water partition coefficient are also important factors in evaluating the newly designed

compounds, the solubility and $\log P$ of representative compounds II-10c, II-10h, and III-15h were studied by high-performance liquid chromatography (HPLC). Table 4 displayed the $\log P$ of the selected compounds is at the appropriate value (accepted range: 1–5). However, the water solubility of the selected compounds is slightly lower than that of PF-74 at three different pH values (7.4, 7.0 and 2.0), which may be a reason for the decrease of anti-HIV-1 activity at the cellular level.




Fig. 3 (a) RMSD (heavy atoms) of amino acids of CA HIV-1 monomer in reference to the first frame of the MD simulation. (b) RMSD (heavy atoms) of the bound II-10c in reference to the docked conformer.






Fig. 4 Binding interactions of II-10c in the first (a) and second (b) clusters.

Table 3 Cell permeability assay of II-10c^a

Compound	Mean P_{app} (10^{-6} cm s ⁻¹)	Rank
	A to B	P_{app}
Nadolol	0.08	Low
Metoprolol	16.40	High
II-10c	<0.01	Low

^a Binning criteria: low permeability: $P_{app} \leq 0.5$ ($\times 10^{-6}$ cm s⁻¹); moderate permeability: $0.5 < P_{app} < 2.5$ ($\times 10^{-6}$ cm s⁻¹); high permeability: $P_{app} \geq 2.5$ ($\times 10^{-6}$ cm s⁻¹).

Table 4 The water solubility of II-10c, II-10h and III-15h

Compound	log P^a	pH = 7.0 ^b (μ g mL ⁻¹)		pH = 7.4 ^b (μ g mL ⁻¹)		pH = 2.0 ^b (μ g mL ⁻¹)	
		1 ^c	2 ^d	1 ^c	2 ^d	1 ^c	2 ^d
PF-74	1.96	7.85	7.84	9.30	9.37	17.96	18.01
II-10c	2.29	4.02	4.09	3.92	3.89	9.29	9.35
II-10h	2.07	2.71	2.69	2.66	2.73	5.05	5.14
III-15h	2.36	3.23	3.29	3.01	3.10	5.94	5.85

^a log P : logarithm of partition coefficient, measured by HPLC.

^b Measured in phosphate buffer by HPLC method in duplicate. ^c Data from the first test. ^d Data from the second test.

3. Conclusion

In summary, taking the most extensively studied HIV-1 capsid inhibitor PF-74 as lead compound, a novel series of 1,2,3-triazole phenylalanine derivatives were designed, synthesized and biologically evaluated. Among them, compound II-10c ($EC_{50} = 2.13$ μ M, $CC_{50} > 35.49$ μ M) exhibited remarkable anti-HIV-1 activity. Then, the preliminary SARs were discussed comprehensively to obtain valuable information. Of course, there is no reasonable explanation for some SARs at present, which reflects

the unpredictability of structural modification of the protein-solvent interface due to flexibility.³⁵ To better understand the interactions between HIV-1 CA protein and the newly synthesized compounds, MD simulation was performed for the representative compounds. SPR binding assays shown that II-10c and lead compound PF-74 have similar affinity for HIV-1 CA monomer, but PF-74 prefers to interact with HIV-1 CA hexamer. Therefore, in the further design, we should focus on the modification of PF-74 within the CTD-NTD interface, which may improve the affinity of the compounds with HIV-1 CA hexamer to improve the antiviral activity. Further investigation showed that the weak permeability and water solubility of these compounds were probably the important factors that are restricting their cell-based activity. Thus, in future research, we should pay attention to the evaluation of drug-like properties³⁶ while improving the activity of compounds. Generally, we analyzed the potential reasons for the anti-HIV-1 activity of compounds from various perspectives, which set the foundation for further design and optimization of CA-targeting compounds with improved potency. Further optimizations of this series of compounds are currently ongoing and will be reported in due course.

4. Experimental section

4.1. Chemistry

All melting points of the compounds were determined on a micro melting point apparatus and were uncorrected. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker Avance-400 NMR spectrometer in DMSO or CDCl₃ using TMS as an internal reference. Chemical shifts were expressed in δ units (ppm), and J values were presented in hertz (Hz). Related mass spectra dates were determined by a LC Autosampler Device: Standard G1313A instrument. TLC was performed on Silica Gel GF254 for TLC and spots were visualized by irradiation with UV light ($\lambda = 254$ nm). Meanwhile, flash column chromatography was performed on column packed with Silica Gel 60 (200–300



mesh). Rotary evaporator under reduced pressure condition was used to concentrate the reaction solutions. Solvents were of reagent grade and purified with standard methods when necessary. All azide substituents were synthesized by our group in the early stage.⁷

4.1.1. *tert*-Butyl (*S*)-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)carbamate (5). A solution of (*S*)-2-((*tert*-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (4, 8.75 mmol, 2.7 g) in 15 mL dichloromethane was added PyBop (10.9 mmol, 5.7 g) at 0 °C, and the mixture stirred for 0.5 h. Subsequently, DIEA (21.87 mmol, 3.61 mL) and 4-methoxy-*N*-methylaniline (7.29 mmol, 1.0 g) were added to the mixture and then stirred at room temperature for another 8–9 h (monitored by TLC). The resulting mixture was evaporated under reduced pressure and the residue was initially washed by 1 N HCl and extracted with ethyl acetate (3 × 20 mL). Then, the combined organic layer was washed with saturated sodium bicarbonate (3 × 50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford corresponding crude intermediate 5 as yellow oil with a yield of 88%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.31 (d, *J* = 8.4 Hz, 2H), 7.22–6.89 (m, 4H), 6.43 (d, *J* = 8.0 Hz), 4.27–4.05 (m, 1H), 3.80 (s, 3H), 3.14 (s, 3H), 2.92–2.55 (m, 2H), 1.29 (s, 9H). ESI-MS: *m/z* 421.21 (M + H)⁺, C₂₂H₂₆F₂N₂O₄ (420.19).

4.1.2. (*S*)-2-Amino-3-(3,5-difluorophenyl)-*N*-(4-methoxyphenyl)-*N*-methylpropanamide (6). Trifluoroacetic acid (34.2 mmol, 5.0 eq.) was added dropwise to intermediate 5 (2.86 g, 6.84 mmol, 1.0 eq.) in 30 mL dichloromethane and stirred at room temperature for 6–7 h. Then, the resulting mixture solution was alkalinized to pH = 9 with saturated sodium bicarbonate solution, and then extracted with dichloromethane (3 × 20 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to yield the crude product 6 as yellow oil, which was directly injected the next step. ESI-MS: *m/z* 321.00 (M + H)⁺, 343.08 (M + Na)⁺, C₁₇H₁₈F₂N₂O₂ (320.13).

4.1.3. (*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)propionamide (7). Propionic acid (4.22 mmol, 0.3 g) and HATU (5.28 mmol, 2.0 g) were mixed in dichloromethane and stirred in an ice bath for 1 h. Then, the intermediate 6 (6.33 mmol, 2.35 g) and DIEA (7.03 mmol, 1.16 mL) were added to the above solution slowly at 0 °C. The reaction system was then stirred at room temperature for additional 12 h. The solvent was removed under reduced pressure and then 1 N HCl (30 mL) was added, extracted with ethyl acetate (3 × 30 mL). The combined organic layer was washed with saturated sodium bicarbonate (3 × 50 mL). The resulting organic layer was washed with saturated salt water, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford corresponding crude product, which was purified by flash column chromatography to yield compound 7 as yellow oil with the yield of 42%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (d, *J* = 7.7 Hz, 1H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.12–6.93 (m, 3H), 6.57–6.36 (m, 2H), 4.47–4.29 (m, 1H), 4.18 (s, 1H), 3.80 (s, 3H), 3.13 (s, 3H), 2.90–2.70 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.33, 163.64 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.24, 151.89, 142.49 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.74, 129.22, 115.30, 112.35 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.64 (t, ³*J*_{CF} = 25.3 Hz, 1C),

78.14, 77.10, 55.95, 52.20, 37.81, 36.21. ESI-MS: *m/z* 373.2 (M + H)⁺, C₂₀H₁₈F₂N₂O₃ (372.13).

4.1.4. General procedure for the synthesis of target compounds I-8(a-u). The key intermediate 7 (1.0 eq.), azide substituents (1.1 eq.), ascorbic acid sodium (0.6 eq.) and CuSO₄·5H₂O (0.3 eq.) were dissolved in the solution of tetrahydrofuran/water (*v* : *v* = 1 : 1). The resulting mixture was stirred at 30–60 °C for 4–6 h. Then the reaction mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic phase was washed with saturated salt water (3 × 10 mL), dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to give the corresponding crude target product, which was purified by flash column chromatography to afford product I-8(a-u). Yield: 60–80%.

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(2-methylbenzyl)-1*H*-1,2,3-triazole-4-carboxamide (I-8a). Pale green solid, yield: 61%, mp: 76–78 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.52 (d, *J* = 8.2 Hz, 1H), 8.49 (s, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.31–7.23 (m, 2H), 7.20 (td, *J* = 7.1, 2.2 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 3H), 7.00 (td, *J* = 8.3, 7.1, 4.6 Hz, 1H), 6.62–6.40 (m, 2H), 5.67 (s, 2H), 4.66 (td, *J* = 8.9, 4.1 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.05–2.84 (m, 2H), 2.31 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 170.85, 163.60 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.74, 159.23, 142.82 (t, ²*J*_{CF} = 9.1 Hz, 1C), 142.47, 136.74, 135.85, 134.21, 130.94, 129.31, 129.06, 128.92, 127.17, 126.79, 115.31, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.95, 51.69, 51.58, 37.83, 36.47, 19.08. ESI-MS: *m/z* 520.4 (M + H)⁺, C₂₈H₂₇F₂N₅O₃ (519.21).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(3-methylbenzyl)-1*H*-1,2,3-triazole-4-carboxamide (I-8b). Pale green solid, yield: 66%, mp: 78–80 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.53 (d, *J* = 8.1 Hz, 1H), 8.49 (s, 1H), 7.34 (d, *J* = 8.5 Hz, 2H), 7.30–7.17 (m, 3H), 7.07 (dd, *J* = 7.8, 5.5 Hz, 3H), 7.01 (ddd, *J* = 9.6, 7.1, 2.4 Hz, 1H), 6.61–6.45 (m, 2H), 5.67 (s, 2H), 4.66 (t, *J* = 4.4 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.05–2.79 (m, 2H), 2.31 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 170.85, 163.59 (dd, ¹*J*_{CF} = 246.4 Hz, ¹*J*_{CF} = 13.1 Hz, 2C), 159.74, 159.23, 142.82 (t, ²*J*_{CF} = 9.1 Hz, 1C), 142.47, 136.74, 135.85, 134.21, 130.94, 129.31, 129.05, 128.92, 127.18, 126.79, 115.30, 112.45 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.95, 51.69, 51.59, 37.83, 36.46, 19.08. ESI-MS: *m/z* 520.5 (M + H)⁺, C₂₈H₂₇F₂N₅O₃ (519.21).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(4-methylbenzyl)-1*H*-1,2,3-triazole-4-carboxamide (I-8c). Pale green solid, yield: 69%, mp: 82–84 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.56 (s, 1H), 8.50 (d, *J* = 8.1 Hz, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.21 (q, *J* = 8.0 Hz, 3H), 7.14–6.89 (m, 4H), 6.62–6.43 (m, 2H), 5.59 (s, 2H), 4.66 (td, *J* = 9.0, 4.2 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.05–2.77 (m, 2H), 2.28 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 170.85, 163.59 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.78, 159.23, 142.83 (t, ²*J*_{CF} = 9.1 Hz, 1C), 142.59, 138.11, 135.85, 133.10, 131.90, 129.80, 129.31, 128.44, 127.04, 115.31, 112.45 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.47 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.95, 53.34, 51.57, 37.83, 36.45, 21.16. ESI-MS: *m/z* 520.4 (M + H)⁺, C₂₈H₂₇F₂N₅O₃ (519.21).

(*S*)-1-(2-Chlorobenzyl)-*N*-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1*H*-1,2,3-triazole-4-



carboxamide (I-8d). White solid, yield: 64%, mp: 92–94 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.54 (s, 1H), 8.50 (d, *J* = 8.1 Hz, 1H), 7.53 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.47–7.36 (m, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.25 (dd, *J* = 7.3, 2.0 Hz, 1H), 7.14–6.90 (m, 3H), 6.51 (d, *J* = 7.7 Hz, 2H), 5.76 (s, 2H), 4.67 (td, *J* = 8.7, 4.1 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.05–2.77 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.85, 163.74 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13 Hz, 2C), 159.70, 159.24, 142.41 (t, ²*J*_{CF} = 9 Hz, 1C), 135.86, 133.31, 133.11, 131.02, 130.87, 130.15, 129.31, 128.25, 127.58, 115.32, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 51.60, 51.42, 37.84, 36.47. ESI-MS: *m/z* 540.4 (M + H)⁺, C₂₇H₂₄ClF₂N₅O₅ (539.15).

(S)-1-(3-Chlorobenzyl)-N-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1H-1,2,3-triazole-4-carboxamide (I-8e). Pale yellow solid, yield: 65%, mp: 75–77 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.65 (s, 1H), 8.54 (d, *J* = 8.1 Hz, 1H), 7.50–7.40 (m, 3H), 7.35 (dd, *J* = 9.5, 2.9 Hz, 2H), 7.28 (td, *J* = 5.1, 2.3 Hz, 1H), 7.06 (d, *J* = 8.6 Hz, 2H), 7.00 (tt, *J* = 9.3, 2.3 Hz, 1H), 6.65–6.41 (m, 2H), 5.68 (s, 2H), 4.67 (td, *J* = 8.9, 4.0 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.06–2.81 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.83, 163.73 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.73, 159.23, 142.69 (t, ²*J*_{CF} = 9.1 Hz, 1C), 138.44, 135.85, 133.78, 131.23, 129.32, 128.74, 128.35, 127.39, 127.15, 115.31, 112.45 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.95, 52.76, 51.61, 37.84, 36.44. ESI-MS: *m/z* 540.4 (M + H)⁺, C₂₇H₂₄ClF₂N₅O₅ (539.15).

(S)-1-(4-chlorobenzyl)-N-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1H-1,2,3-triazole-4-carboxamide (I-8f). White solid, yield: 74%, mp: 86–88 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.62 (s, 1H), 8.53 (d, *J* = 8.1 Hz, 1H), 7.45 (d, *J* = 8.3 Hz, 2H), 7.35 (dd, *J* = 8.5, 4.4 Hz, 4H), 7.06 (d, *J* = 8.5 Hz, 2H), 7.00 (tt, *J* = 9.5, 2.4 Hz, 1H), 6.51 (h, *J* = 4.3 Hz, 2H), 5.66 (s, 2H), 4.67 (td, *J* = 9.0, 4.0 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.04–2.86 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.84, 163.73 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13 Hz, 2C), 159.75, 159.24, 142.67 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.85, 135.07, 133.47, 130.37, 129.27, 127.29, 115.32, 112.45 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.47 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.95, 52.73, 51.60, 37.83, 36.45. ESI-MS: *m/z* 540.4 (M + H)⁺, C₂₇H₂₄ClF₂N₅O₅ (539.15).

(S)-1-(2-Cyanobenzyl)-N-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1H-1,2,3-triazole-4-carboxamide (I-8g). Brownish yellow solid, yield: 78%, mp: 80–82 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.63 (s, 1H), 8.56 (d, *J* = 8.1 Hz, 1H), 7.97–7.89 (m, 1H), 7.74 (td, *J* = 7.7, 1.3 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.37 (dd, *J* = 14.4, 8.2 Hz, 3H), 7.07 (d, *J* = 8.4 Hz, 2H), 7.04–6.90 (m, 1H), 6.64–6.34 (m, 2H), 5.88 (s, 2H), 4.84–4.53 (m, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 3.04–2.80 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.84, 163.73 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.66, 159.24, 142.56 (t, ²*J*_{CF} = 9.1 Hz, 1C), 138.84, 135.86, 134.35, 133.91, 129.88, 129.78, 129.32, 127.78, 117.38, 115.32, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 111.65, 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 51.78, 51.62, 37.84, 36.45. ESI-MS: *m/z* 531.4 (M + H)⁺, C₂₈H₂₄F₂N₆O₃ (530.19).

(S)-1-(3-Cyanobenzyl)-N-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1H-1,2,3-triazole-4-

carboxamide (I-8h). Pale yellow solid, yield: 67%, mp: 79–81 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.71 (s, 1H), 8.58 (d, *J* = 8.7 Hz, 1H), 7.97–7.83 (m, 2H), 7.67 (dt, *J* = 15.2, 7.8 Hz, 2H), 7.39 (d, *J* = 8.6 Hz, 2H), 7.19–6.94 (m, 3H), 6.72–6.44 (m, 2H), 5.78 (s, 2H), 4.72 (td, *J* = 8.9, 4.0 Hz, 1H), 3.86 (s, 3H), 3.20 (s, 3H), 3.11–2.82 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.82, 163.73 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.70, 159.24, 142.73 (t, ²*J*_{CF} = 9.1 Hz, 1C), 137.57, 135.85, 133.43, 132.59, 132.25, 130.60, 129.31, 127.49, 118.84, 115.32, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.47 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 52.60, 51.58, 37.84, 36.46. ESI-MS: *m/z* 531.4 (M + H)⁺, C₂₈H₂₄F₂N₆O₃ (530.19).

(S)-1-(4-Cyanobenzyl)-N-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1H-1,2,3-triazole-4-carboxamide (I-8i). White solid, yield: 75%, mp: 82–84 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.66 (s, 1H), 8.55 (d, *J* = 8.1 Hz, 1H), 7.87 (d, *J* = 8.1 Hz, 2H), 7.48 (d, *J* = 8.0 Hz, 2H), 7.43–7.29 (m, 2H), 7.07 (d, *J* = 8.6 Hz, 2H), 6.99 (dt, *J* = 9.3, 2.5 Hz, 1H), 6.67–6.40 (m, 2H), 5.78 (s, 2H), 4.67 (td, *J* = 8.9, 3.9 Hz, 1H), 3.81 (s, 3H), 3.16 (s, 3H), 3.11–2.77 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.83, 163.59 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.71, 159.24, 142.73 (t, ²*J*_{CF} = 9.1 Hz, 1C), 141.50, 135.85, 133.24, 129.32, 129.19, 127.65, 118.96, 115.32, 112.45 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 111.51, 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 52.91, 51.63, 37.84, 36.42. ESI-MS: *m/z* 531.4 (M + H)⁺, C₂₈H₂₄F₂N₆O₃ (530.19).

(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1-(2-nitrobenzyl)-1H-1,2,3-triazole-4-carboxamide (I-8j). Yellow solid, yield: 65%, mp: 84–86 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.72–8.51 (m, 2H), 8.17 (dd, *J* = 8.2, 1.3 Hz, 1H), 7.76 (td, *J* = 7.6, 1.3 Hz, 1H), 7.66 (td, *J* = 7.8, 1.4 Hz, 1H), 7.35 (d, *J* = 8.5 Hz, 2H), 7.17–6.92 (m, 4H), 6.52 (h, *J* = 4.3 Hz, 2H), 6.03 (s, 2H), 4.68 (td, *J* = 8.9, 4.0 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 3.06–2.82 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.85, 163.74 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.70, 159.25, 147.99, 142.55 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.86, 134.93, 130.86, 130.62, 130.26, 129.32, 128.01, 125.64, 115.32, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 51.65, 50.81, 37.84, 36.43. ESI-MS: *m/z* 551.4 (M + H)⁺, C₂₇H₂₄F₂N₆O₅ (550.18).

(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1-(3-nitrobenzyl)-1H-1,2,3-triazole-4-carboxamide (I-8k). White solid, yield: 65%, mp: 84–86 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.68 (s, 1H), 8.50 (d, *J* = 8.1 Hz, 1H), 8.25 (d, *J* = 1.9 Hz, 1H), 8.21 (dd, *J* = 8.0, 2.3 Hz, 1H), 7.78 (d, *J* = 7.7 Hz, 1H), 7.69 (t, *J* = 7.9 Hz, 1H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.05 (d, *J* = 8.4 Hz, 2H), 6.98 (td, *J* = 9.4, 4.6 Hz, 1H), 6.63–6.40 (m, 2H), 5.83 (s, 2H), 4.68 (td, *J* = 8.9, 4.1 Hz, 1H), 3.32 (s, 3H), 3.15 (s, 3H), 3.06–2.80 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 170.81, 163.74 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.68, 159.25, 148.39, 142.76 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.86, 135.21, 130.93, 129.29, 127.54, 123.72, 123.38, 115.33, 112.46 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.46 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 52.53, 51.56, 37.84, 36.53. ESI-MS: *m/z* 551.3 (M + H)⁺, C₂₇H₂₄F₂N₆O₅ (550.18).

(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methylamino)-1-oxopropan-2-yl)-1-(4-nitrobenzyl)-1H-1,2,3-triazole-4-carboxamide (I-8l). Brown solid, yield: 63%, mp: 182–184 °C. ¹H NMR (400



MHz, DMSO- d_6) δ 8.67 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H), 8.24 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.5 Hz, 2H), 6.99 (t, J = 9.3 Hz, 1H), 6.52 (d, J = 7.7 Hz, 2H), 5.84 (s, 2H), 4.69 (dt, J = 8.8, 4.5 Hz, 1H), 3.81 (s, 3H), 3.16 (s, 3H), 3.05–2.82 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.82, 163.75 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 161.17, 159.68, 159.26, 147.79, 143.42, 142.77 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 135.87, 129.52, 129.30, 129.12, 127.70, 124.40, 115.34, 112.46 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.47 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.97, 52.66, 51.58, 37.84, 36.51. ESI-MS: m/z 551.4 (M + H) $^+$, $\text{C}_{27}\text{H}_{24}\text{F}_2\text{N}_6\text{O}_5$ (550.18).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(naphthalen-1-ylmethyl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8m**). White solid, yield: 68%, mp: 90–92 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.54 (s, 1H), 8.49 (d, J = 8.1 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.99 (dd, J = 9.6, 7.6 Hz, 2H), 7.66–7.46 (m, 3H), 7.42 (d, J = 7.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.12–6.89 (m, 3H), 6.63–6.41 (m, 2H), 6.15 (s, 2H), 4.64 (td, J = 8.8, 4.2 Hz, 1H), 3.79 (s, 3H), 3.13 (s, 3H), 3.03–2.83 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.83, 163.72 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.70, 159.22, 142.48 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 135.84, 133.83, 131.55, 130.97, 129.65, 129.28, 129.19, 127.77, 127.34, 127.25, 126.69, 126.04, 123.58, 115.29, 112.20 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.47 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.94, 51.55, 37.82, 36.48. ESI-MS: m/z 556.3 (M + H) $^+$, $\text{C}_{31}\text{H}_{27}\text{F}_2\text{N}_5\text{O}_3$ (555.21).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(naphthalen-2-ylmethyl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8n**). White solid, yield: 67%, mp: 89–91 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.66 (s, 1H), 8.50 (d, J = 8.1 Hz, 1H), 7.99–7.89 (m, 3H), 7.87 (s, 1H), 7.59–7.50 (m, 2H), 7.45 (dd, J = 8.4, 1.8 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 6.99 (td, J = 8.2, 7.0, 4.6 Hz, 1H), 6.59–6.40 (m, 2H), 5.83 (s, 2H), 4.67 (td, J = 8.9, 4.2 Hz, 1H), 3.80 (s, 3H), 3.15 (s, 3H), 3.06–2.81 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.83, 163.72 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.76, 159.23, 142.65 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 135.86, 133.58, 133.21, 133.00, 129.30, 129.04, 128.30, 128.09, 127.41, 127.32, 127.07, 126.97, 126.07, 115.32, 112.21 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.47 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.95, 53.73, 51.56, 37.83, 36.51. ESI-MS: m/z 556.3 (M + H) $^+$, $\text{C}_{31}\text{H}_{27}\text{F}_2\text{N}_5\text{O}_3$ (555.21).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(quinolin-2-yl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8o**). White solid, yield: 71%, mp: 205–207 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 9.48 (d, J = 2.6 Hz, 1H), 9.44 (s, 1H), 9.01 (d, J = 2.6 Hz, 1H), 8.75 (d, J = 8.1 Hz, 1H), 8.25–8.05 (m, 2H), 7.90 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.83–7.69 (m, 1H), 7.39 (d, J = 8.5 Hz, 2H), 7.24–6.90 (m, 3H), 6.75–6.32 (m, 2H), 4.89–4.61 (m, 1H), 3.83 (s, 3H), 3.19 (s, 3H), 3.16–2.84 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.79, 163.76 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.44, 159.27, 147.55, 143.87, 143.56, 142.86 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 135.88, 131.22, 130.31, 129.39, 129.19, 128.64, 127.39, 127.24, 126.20, 115.36, 112.20 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.52 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.97, 51.75, 37.90, 36.46. ESI-MS: m/z 543.5 (M + H) $^+$, $\text{C}_{25}\text{H}_{24}\text{F}_2\text{N}_6\text{O}_3$ (542.19).

Methyl (*S*)-4-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)carbamoyl)-1*H*-1,2,3-triazol-1-yl)benzoate (**I-**

8p). White solid, yield: 65%, mp: 85–87 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 9.37 (s, 1H), 8.70 (d, J = 8.1 Hz, 1H), 8.48 (t, J = 1.8 Hz, 1H), 8.29–8.18 (m, 1H), 8.09 (dd, J = 7.9, 1.4 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.23–6.93 (m, 3H), 6.66–6.41 (m, 2H), 4.73 (td, J = 8.9, 4.0 Hz, 1H, CHCO), 3.92 (s, 3H, COOCH₃), 3.82 (s, 3H, OCH₃), 3.18 (s, 3H, NCH₃), 3.11–2.79 (m, 2H, CH₂). ^{13}C NMR (100 MHz, DMSO) δ 170.79, 165.66, 163.75 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.44, 159.26, 143.49, 142.83 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 136.97, 135.87, 131.73, 131.08, 130.01, 129.34, 125.73, 125.50, 121.26, 115.34, 112.26 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.51 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.96, 53.07, 51.71, 37.88, 36.49. ESI-MS: m/z 550.4 (M + H) $^+$, $\text{C}_{28}\text{H}_{25}\text{F}_2\text{N}_5\text{O}_5$ (549.18).

(*S*)-1-(Benzo[d][1,3]dioxol-5-yl)-*N*-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8q**). White solid, yield: 78%, mp: 83–85 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 9.10 (s, 1H), 8.62 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.45–7.26 (m, 3H), 7.10 (dd, J = 16.7, 8.5 Hz, 3H), 7.05–6.96 (m, 1H), 6.66–6.46 (m, 2H), 6.16 (s, 2H), 4.71 (td, J = 8.9, 4.0 Hz, 1H), 3.35 (s, 3H), 3.17 (s, 3H), 3.09–2.89 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.81, 163.75 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.57, 159.26, 148.63, 148.29, 143.12, 142.82 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 135.87, 131.03, 129.33, 125.52, 115.33, 114.91, 112.26 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 109.10, 102.85, 102.71, 102.50, 102.20 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.96, 51.65, 37.87, 36.51. ESI-MS: m/z 536.3 (M + H) $^+$, $\text{C}_{27}\text{H}_{23}\text{F}_2\text{N}_5\text{O}_5$ (535.17).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(4-sulfanoylbenzyl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8r**). White solid, yield: 80%, mp: 107–109 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.65 (s, 1H), 8.54 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 8.1 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 7.42–7.31 (m, 4H), 7.12–6.96 (m, 3H), 6.62–6.39 (m, 2H), 5.76 (s, 2H), 4.67 (d, J = 3.8 Hz, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 3.05–2.80 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.84, 163.60 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.74, 159.24, 144.36, 142.70 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 139.84, 135.85, 129.32, 128.83, 127.51, 126.64, 115.32, 112.46 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.49 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.96, 52.92, 51.62, 37.84, 36.43. ESI-MS: m/z 585.3 (M + H) $^+$, $\text{C}_{27}\text{H}_{26}\text{F}_2\text{N}_6\text{O}_5\text{S}$ (584.17).

(*S*)-1-(4-Carbamoylbenzyl)-*N*-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8s**). White solid, yield: 76%, mp: 109–111 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.63 (s, 1H), 8.51 (d, J = 8.1 Hz, 1H), 7.98 (s, 1H), 7.87 (d, J = 7.9 Hz, 2H), 7.37 (dt, J = 13.8, 7.2 Hz, 5H), 7.15–6.93 (m, 3H), 6.52 (d, J = 7.7 Hz, 2H), 5.72 (s, 2H), 4.68 (td, J = 9.0, 4.1 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 3.07–2.81 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.84, 167.86, 163.74 (dd, $^1J_{\text{CF}}$ = 246.4 Hz, $^3J_{\text{CF}}$ = 13.1 Hz, 2C), 159.74, 159.24, 142.67 (t, $^2J_{\text{CF}}$ = 9.1 Hz, 1C), 139.06, 135.86, 134.66, 129.31, 128.42, 128.15, 127.38, 115.33, 112.47 (dd, $^2J_{\text{CF}}$ = 19.2 Hz, $^4J_{\text{CF}}$ = 6.1 Hz, 2C), 102.48 (t, $^3J_{\text{CF}}$ = 25.3 Hz, 1C), 55.96, 53.14, 51.58, 37.85, 36.50. ESI-MS: m/z 549.4 (M + H) $^+$, $\text{C}_{27}\text{H}_{26}\text{F}_2\text{N}_6\text{O}_4$ (548.20).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(phenylsulfonyl)methyl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8t**). White solid, yield: 62%, mp: 95–97 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.71 (d, J = 8.0 Hz, 1H), 8.49 (s,



1H), 7.96–7.78 (m, 1H), 7.75–7.69 (m, 2H), 7.65 (t, $J = 7.7$ Hz, 2H), 7.37 (d, $J = 8.5$ Hz, 2H), 7.08 (d, $J = 8.6$ Hz, 2H), 7.05–6.96 (m, 1H), 6.65–6.47 (m, 2H), 6.40 (d, $J = 2.6$ Hz, 2H), 4.64 (td, $J = 9.0, 3.9$ Hz, 1H), 3.82 (s, 3H), 3.17 (s, 3H), 3.02–2.76 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 170.80, 163.60 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.26, 159.21, 142.49 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 136.22, 135.85, 135.48, 130.07, 129.35, 129.00, 128.57, 115.33, 112.43 (dd, $^2J_{\text{CF}} = 19.2$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 102.52 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C), 67.45, 55.97, 51.83, 37.85, 36.26. ESI-MS: m/z 570.4 (M + H)⁺, C₂₇H₂₅F₂N₅O₅S (569.15).

N-((*S*)-3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-1-(2-(hydroxymethyl)-5-(5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl)tetrahydrofuran-3-yl)-1*H*-1,2,3-triazole-4-carboxamide (**I-8u**).

White solid, yield: 66%, mp: 142–144 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 11.38 (s, 1H), 8.73 (s, 1H), 8.55 (d, $J = 8.2$ Hz, 1H), 7.82 (s, 1H), 7.36 (d, $J = 8.4$ Hz, 2H), 7.16–6.93 (m, 3H), 6.64–6.48 (m, 2H), 6.42 (t, $J = 6.6$ Hz, 1H), 5.54–5.34 (m, 1H), 5.29 (t, $J = 5.2$ Hz, 1H), 4.69 (d, $J = 3.9$ Hz, 1H), 4.34–4.16 (m, 1H), 3.82 (s, 3H), 3.66 (dt, $J = 20.3, 4.7$ Hz, 2H), 3.16 (s, 3H), 3.06–2.84 (m, 2H), 2.83–2.59 (m, 2H), 1.82 (s, 3H). ^{13}C NMR (100 MHz, DMSO) δ 170.84, 164.20 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.74, 159.25, 150.89, 142.61 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 136.73, 135.85, 129.33, 126.83, 115.34, 112.46 (dd, $^2J_{\text{CF}} = 19.2$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 110.12, 102.49 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C), 84.72, 84.28, 61.09, 60.06, 55.97, 51.59, 37.85, 36.46, 12.73. ESI-MS: m/z 640.4 (M + H)⁺, C₃₀H₃₁F₂N₇O₇ (639.23).

4.1.5. (S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-ethynylbenzamide (9). 3-Ethynylbenzoic acid (4.22 mmol, 0.62 g) and HATU (5.28 mmol, 2.0 g) were mixed in dichloromethane and stirred in an ice bath for 1 h. Then, the intermediate **6** (6.33 mmol, 2.35 g) and DIEA (7.03 mmol, 1.16 mL) were added to the above solution slowly at 0 °C. The reaction system was then stirred at room temperature for additional 12 h. The solvent was removed under reduced pressure and then 1 N HCl (30 mL) was added, extracted with ethyl acetate (3 × 30 mL). The combined organic layer was washed with saturated sodium bicarbonate (3 × 50 mL). The resulting organic layer was washed with saturated salt water, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford corresponding crude product, which was purified by flash column chromatography to yield compound **9** as pale yellow solid with the yield of 39%. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.85 (d, $J = 7.9$ Hz, 1H), 7.95 (t, $J = 1.7$ Hz, 1H), 7.82 (dt, $J = 7.8, 1.5$ Hz, 1H), 7.64 (dt, $J = 7.6, 1.4$ Hz, 1H), 7.49 (t, $J = 7.7$ Hz, 1H), 7.40 (d, $J = 8.4$ Hz, 2H), 7.10 (s, 1H), 7.05–6.96 (m, 1H), 6.61–6.35 (m, 2H), 4.74–4.55 (m, 1H), 4.32 (s, 1H), 3.82 (s, 3H), 3.17 (s, 3H), 3.01–2.84 (m, 2H), 2.69 (s, 1H). ^{13}C NMR (100 MHz, DMSO) δ 171.16, 165.82, 163.62 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.24, 143.12 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 135.95, 134.91, 134.41, 130.92, 129.35, 128.50, 122.20, 115.31, 112.08 (dd, $^2J_{\text{CF}} = 19.2$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 102.49 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C) 83.24, 81.96, 55.97, 52.73, 38.70, 37.84, 36.21. ESI-MS: m/z 447.07 (M – H)[–], C₂₆H₂₂F₂N₂O₃ (448.16).

4.1.6. General procedure for the synthesis of target compounds II-10(a–o). The key intermediate **9** (1.0 eq.), azide substituents (1.1 eq.), ascorbic acid sodium (0.6 eq.) and

CuSO₄·5H₂O (0.3 eq.) were dissolved in the solution of tetrahydrofuran/water (v : v = 1 : 1). The resulting mixture was stirred at 30–60 °C for 4–6 h. Then the reaction mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic phase was washed with saturated salt water (3 × 10 mL), dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to give the corresponding crude target product, which was purified by flash column chromatography to afford product **II-10(a–o)**. Yield: 65–80%.

*(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(2-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)benzamide (II-10a).* Pale yellow solid, yield: 78%, mp: 70–72 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.87 (d, $J = 7.8$ Hz, 1H), 8.67 (s, 1H), 8.32 (t, $J = 1.8$ Hz, 1H), 8.19 (dd, $J = 8.2, 1.3$ Hz, 1H), 8.01 (d, $J = 7.7$ Hz, 1H), 7.78 (td, $J = 7.6, 1.4$ Hz, 2H), 7.71–7.62 (m, 1H), 7.55 (t, $J = 7.8$ Hz, 1H), 7.40 (d, $J = 8.4$ Hz, 2H), 7.19 (d, $J = 7.7$ Hz, 1H), 7.09 (d, $J = 8.4$ Hz, 2H), 7.06–6.87 (m, 1H), 6.63–6.48 (m, 2H), 6.06 (s, 2H), 4.74–4.63 (m, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 2.98 (h, $J = 9.3, 8.9$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.30, 166.50, 163.75 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.22, 148.06, 146.50, 143.15 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 135.99, 134.96, 134.75, 131.10, 131.06, 130.78, 130.22, 129.41, 129.36, 128.56, 127.39, 125.63, 124.76, 123.12, 115.28, 112.37 (dd, $^2J_{\text{CF}} = 19.2$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 102.49 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C), 55.97, 52.67, 50.74, 37.84, 36.31. ESI-MS: m/z 627.3 (M + H)⁺, C₃₃H₂₈F₂N₆O₅ (626.61).

*(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(3-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)benzamide (II-10b).* Pale yellow solid, yield: 72%, mp: 69–71 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.86 (d, $J = 7.8$ Hz, 1H), 8.76 (s, 1H), 8.42–8.28 (m, 2H), 8.24 (dd, $J = 8.2, 2.3$ Hz, 1H), 8.00 (d, $J = 7.7$ Hz, 1H), 7.83 (d, $J = 7.7$ Hz, 1H), 7.77 (d, $J = 7.8$ Hz, 1H), 7.72 (t, $J = 8.0$ Hz, 1H), 7.55 (t, $J = 7.8$ Hz, 1H), 7.40 (d, $J = 8.3$ Hz, 2H), 7.09 (d, $J = 8.4$ Hz, 2H), 7.01 (tt, $J = 9.6, 2.4$ Hz, 1H), 6.65–6.46 (m, 2H), 5.88 (s, 2H), 4.67 (td, $J = 8.5, 4.6$ Hz, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 2.98 (h, $J = 9.3$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.30, 166.50, 163.75 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.22, 148.39, 146.70, 143.15 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 138.41, 135.99, 135.25, 134.76, 131.07, 130.97, 129.40, 129.35, 128.52, 127.35, 124.76, 123.69, 123.39, 122.66, 115.28, 112.37 (dd, $^2J_{\text{CF}} = 19.2$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 102.48 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C), 65.50, 55.96, 52.67, 52.52, 37.84, 36.29. ESI-MS: m/z 627.3 (M + H)⁺, C₃₃H₂₈F₂N₆O₅ (626.61).

*(S)-N-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)benzamide (II-10c).* Yellow solid, yield: 77%, mp: 82–84 °C. ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.86 (d, $J = 7.9$ Hz, 1H), 8.76 (s, 1H), 8.33 (s, 1H), 8.27 (d, $J = 8.4$ Hz, 2H), 8.00 (d, $J = 7.7$ Hz, 1H), 7.78 (d, $J = 7.8$ Hz, 1H), 7.64–7.50 (m, 3H), 7.40 (d, $J = 8.3$ Hz, 2H), 7.09 (d, $J = 8.4$ Hz, 2H), 7.01 (td, $J = 8.3, 7.4, 4.7$ Hz, 1H), 6.66–6.38 (m, 2H), 5.88 (s, 2H), 4.67 (td, $J = 8.7, 4.6$ Hz, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 2.98 (h, $J = 9.3, 8.8$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.30, 166.49, 163.76 (dd, $^1J_{\text{CF}} = 246.4$ Hz, $^3J_{\text{CF}} = 13.1$ Hz, 2C), 159.23, 147.74, 146.72, 143.79, 143.16 (t, $^2J_{\text{CF}} = 9.1$ Hz, 1C), 135.99, 134.75, 131.06, 129.52, 129.41, 129.36, 128.53, 127.37, 124.77, 124.45, 122.84, 115.28, 112.37 (dd, $^2J_{\text{CF}} = 19.1$ Hz, $^4J_{\text{CF}} = 6.1$ Hz, 2C), 102.49 (t, $^3J_{\text{CF}} = 25.3$ Hz, 1C), 65.50, 55.97, 52.66, 37.84, 36.30. ESI-MS: m/z 627.3 (M + H)⁺, C₃₃H₂₈F₂N₆O₅ (626.61).



(*S*)-3-(1-(4-Carbamoylbenzyl)-1*H*-1,2,3-triazol-4-yl)-*N*-(3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)benzamide (**II-10d**). Pale yellow solid, yield: 80%, mp: 94–96 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.84 (d, *J* = 7.9 Hz, 1H), 8.71 (s, 1H), 8.32 (s, 1H), 8.00 (d, *J* = 6.2 Hz, 2H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.86–7.65 (m, 2H), 7.54 (t, *J* = 7.8 Hz, 1H), 7.41 (dd, *J* = 13.3, 8.4 Hz, 5H), 7.08 (d, *J* = 8.3 Hz, 2H), 7.05–6.87 (m, 1H), 6.63–6.40 (m, 2H), 5.75 (s, 2H), 4.68 (td, *J* = 8.5, 4.6 Hz, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 3.06–2.86 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.29, 167.88, 166.52, 163.63 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.22, 146.64, 143.15 (t, ²*J*_{CF} = 9.1 Hz, 1C), 139.37, 136.00, 134.76, 134.59, 131.16, 129.38, 128.45, 128.18, 127.30, 124.73, 122.54, 115.28, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 53.16, 52.64, 37.85, 36.33. ESI-MS: *m/z* 625.4 (M + H)⁺, C₃₄H₃₀F₂N₆O₄ (624.23).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(2-oxo-2-(phenylamino)ethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10e**). Pale yellow solid, yield: 66%, mp: 189–191 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.56 (s, 1H), 8.88 (d, *J* = 7.9 Hz, 1H), 8.67 (s, 1H), 8.36 (t, *J* = 1.8 Hz, 1H), 8.03 (d, *J* = 7.7 Hz, 1H), 7.78 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 2H), 7.56 (t, *J* = 7.7 Hz, 1H), 7.45–7.32 (m, 4H), 7.09 (dd, *J* = 8.4, 2.5 Hz, 3H), 7.06–6.95 (m, 1H), 6.63–6.44 (m, 2H), 5.43 (s, 2H), 4.69 (td, *J* = 8.6, 4.6 Hz, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 3.08–2.80 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.30, 166.49, 164.60, 163.63 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.22, 146.14, 143.16 (t, ²*J*_{CF} = 9.1 Hz, 1C), 138.87, 136.00, 134.75, 131.26, 129.41, 128.48, 127.30, 124.60, 123.92, 119.70, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.14, 102.50 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 52.90, 52.64, 37.86, 36.34. ESI-MS: *m/z* 625.3 (M + H)⁺, C₃₄H₃₀F₂N₆O₄ (624.23).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(4-sulfamoylbenzyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10f**). Pale yellow solid, yield: 68%, mp: 122–124 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.85 (d, *J* = 7.9 Hz, 1H), 8.73 (s, 1H), 8.32 (t, *J* = 1.8 Hz, 1H), 8.00 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.93–7.82 (m, 2H), 7.77 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.55 (t, *J* = 7.6 Hz, 3H), 7.47–7.32 (m, 4H), 7.10 (s, 2H), 7.05–6.88 (m, 1H), 6.62–6.46 (m, 2H), 5.79 (s, 2H), 4.68 (td, *J* = 8.7, 4.8 Hz, 1H), 3.82 (s, 3H), 3.18 (s, 3H), 2.98 (t, *J* = 6.6 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.30, 166.50, 163.76 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.23, 146.68, 144.34, 143.15 (t, ²*J*_{CF} = 9.1 Hz, 1C), 140.14, 136.00, 134.76, 129.39, 129.35, 128.85, 128.52, 127.32, 126.65, 124.75, 122.63, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 52.95, 52.64, 37.85, 36.33. ESI-MS: *m/z* 661.2 (M + H)⁺, C₃₃H₃₀F₂N₆O₅S (660.20).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(3-phenylpropyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10g**). White solid, yield: 80%, mp: 119–121 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.86 (d, *J* = 7.8 Hz, 1H), 8.69 (s, 1H), 8.33 (s, 1H), 8.00 (d, *J* = 7.7 Hz, 1H), 7.77 (d, *J* = 7.8 Hz, 1H), 7.55 (t, *J* = 7.7 Hz, 1H), 7.41 (d, *J* = 8.3 Hz, 2H), 7.31 (t, *J* = 7.5 Hz, 2H), 7.27–7.18 (m, 3H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.01 (tt, *J* = 9.4, 2.3 Hz, 1H), 6.55 (h, *J* = 4.2 Hz, 2H), 4.68 (td, *J* = 9.2, 8.7, 4.3 Hz, 1H), 4.44 (t, *J* = 7.0 Hz, 2H), 3.82 (s, 3H), 3.18 (s, 3H), 2.99 (td, *J* =

14.7, 14.2, 9.6 Hz, 2H), 2.62 (t, *J* = 7.6 Hz, 2H), 2.21 (p, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.32, 166.57, 163.76 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.23, 146.31, 143.18 (t, ²*J*_{CF} = 9.1 Hz, 1C), 141.20, 136.01, 134.75, 131.42, 129.35, 128.83, 128.44, 127.14, 126.49, 124.71, 122.13, 115.29, 112.14 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 52.69, 49.61, 37.84, 36.29, 32.36, 31.72. ESI-MS: *m/z* 610.3 (M + H)⁺, C₃₅H₃₃F₂N₅O₃ (609.26).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(2-(thiophen-3-yl)ethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10h**). White solid, yield: 79%, mp: 73–75 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.86 (d, *J* = 7.9 Hz, 1H), 8.59 (s, 1H), 8.30 (t, *J* = 1.7 Hz, 1H), 7.96 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.77 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.54 (t, *J* = 7.7 Hz, 1H), 7.48 (dd, *J* = 4.9, 2.9 Hz, 1H), 7.41 (d, *J* = 8.5 Hz, 2H), 7.25 (dd, *J* = 2.9, 1.2 Hz, 1H), 7.09 (d, *J* = 8.9 Hz, 2H), 7.02 (tt, *J* = 8.1, 2.8 Hz, 2H), 6.64–6.44 (m, 2H), 4.69 (t, *J* = 7.1 Hz, 3H), 3.82 (s, 3H), 3.27 (t, *J* = 7.2 Hz, 2H), 3.18 (s, 3H), 2.99 (td, *J* = 14.1, 9.5 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.31, 166.55, 163.77 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.23, 146.09, 143.17 (t, ²*J*_{CF} = 9.1 Hz, 1C), 138.24, 136.00, 134.76, 131.37, 129.37, 128.68, 128.39, 127.14, 126.71, 124.65, 122.60, 122.14, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 52.68, 50.55, 37.85, 36.30, 30.68. ESI-MS: *m/z* 602.4 (M + H)⁺, C₃₂H₂₉F₂N₅O₃S (601.20).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(quinolin-2-yl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10i**). White solid, yield: 65%, mp: 85–87 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.62 (s, 1H), 9.55 (d, *J* = 2.6 Hz, 1H), 9.02 (d, *J* = 2.5 Hz, 1H), 8.93 (d, *J* = 7.8 Hz, 1H), 8.48 (t, *J* = 1.7 Hz, 1H), 8.22–8.15 (m, 2H), 8.13 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.93–7.84 (m, 2H), 7.77 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 7.65 (q, *J* = 7.6 Hz, 1H), 7.43 (d, *J* = 8.3 Hz, 2H), 7.25–7.06 (m, 2H), 7.02 (tt, *J* = 9.4, 2.4 Hz, 1H), 6.56 (h, *J* = 4.2 Hz, 2H), 4.70 (ddd, *J* = 9.7, 7.6, 4.3 Hz, 1H), 3.83 (s, 3H), 3.20 (s, 3H), 3.00 (qd, *J* = 13.8, 7.1 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.33, 166.54, 163.79 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.25, 147.49, 143.56, 143.17 (t, ²*J*_{CF} = 9.1 Hz, 1C), 136.03, 134.97, 131.01, 130.66, 130.63, 129.55, 129.43, 129.37, 129.12, 128.66, 127.62, 127.57, 126.34, 125.11, 121.07, 115.30, 112.39 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.15, 102.50 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.99, 52.76, 37.86, 36.30. ESI-MS: *m/z* 619.4 (M + H)⁺, C₃₅H₂₈F₂N₆O₃ (618.22).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(naphthalen-2-ylmethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**II-10j**). White solid, yield: 69%, mp: 128–130 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.84 (d, *J* = 7.9 Hz, 1H), 8.74 (s, 1H), 8.32 (t, *J* = 1.7 Hz, 1H), 8.00 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.98–7.88 (m, 4H), 7.84–7.69 (m, 1H), 7.59–7.48 (m, 4H), 7.39 (d, *J* = 8.5 Hz, 2H), 7.08 (d, *J* = 8.8 Hz, 2H), 7.01 (td, *J* = 9.3, 4.7 Hz, 1H), 6.63–6.46 (m, 2H), 5.86 (s, 2H), 4.67 (td, *J* = 8.6, 4.7 Hz, 1H), 3.82 (s, 3H), 3.17 (s, 3H), 3.05–2.82 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.29, 166.52, 163.62 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.22, 146.63, 143.14 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.99, 134.74, 133.84, 133.25, 131.21, 129.36, 129.06, 128.50, 128.31, 128.10, 127.45, 127.27, 127.06, 126.94, 126.19, 124.70, 122.48, 115.28, 112.37 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.48 (t, ³*J*_{CF} = 25.3 Hz, 1C),



55.96, 53.77, 52.64, 37.84, 36.32. ESI-MS: m/z 632.4 ($M + H$)⁺, C₃₁H₃₁F₂N₅O₃ (631.24).

(*S*)-*N*-(3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(naphthalen-1-ylmethyl)-1*H*,2,3-triazol-4-yl)benzamide (**II-10k**). White solid, yield: 68%, mp: 87–89 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (d, *J* = 7.8 Hz, 1H), 8.64 (s, 1H), 8.28 (t, *J* = 1.7 Hz, 1H), 8.22 (d, *J* = 8.2 Hz, 1H), 7.99 (dd, *J* = 9.0, 7.2 Hz, 3H), 7.74 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.64–7.54 (m, 3H), 7.54–7.45 (m, 2H), 7.39 (d, *J* = 8.4 Hz, 2H), 7.15–7.05 (m, 2H), 7.04–6.95 (m, 1H), 6.65–6.43 (m, 2H), 6.18 (s, 2H), 4.66 (td, *J* = 8.6, 4.9 Hz, 1H), 3.81 (s, 3H), 3.17 (s, 3H), 3.05–2.82 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.28, 166.51, 163.62 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.21, 146.47, 143.14 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.99, 134.73, 133.86, 131.77, 131.12, 129.60, 129.33, 129.17, 128.49, 127.88, 127.32, 126.67, 126.09, 124.68, 123.68, 122.45, 115.27, 112.37 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.12, 102.47 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.96, 52.64, 51.61, 37.84, 36.31. ESI-MS: m/z 632.4 ($M + H$)⁺, C₃₁H₃₁F₂N₅O₃ (631.24).

Methyl (*S*)-2-(4-(3-((3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)carbamoyl)phenyl)-1*H*,1,2,3-triazol-1-yl)acetate (**II-10l**). White solid, yield: 74%, mp: 125–127 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.88 (d, *J* = 7.9 Hz, 1H), 8.63 (s, 1H), 8.34 (t, *J* = 1.7 Hz, 1H), 8.01 (d, *J* = 7.4 Hz, 1H), 7.78 (d, *J* = 7.8 Hz, 1H), 7.56 (t, *J* = 7.8 Hz, 1H), 7.40 (d, *J* = 8.3 Hz, 2H), 7.09 (d, *J* = 8.5 Hz, 2H), 7.01 (ddd, *J* = 9.4, 7.0, 2.4 Hz, 1H), 6.67–6.47 (m, 2H), 5.52 (s, 2H), 4.68 (td, *J* = 8.5, 4.6 Hz, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 3.18 (s, 3H), 3.04–2.90 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.29, 168.17, 166.47, 163.63 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.22, 146.34, 143.16 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.99, 134.77, 132.00, 131.04, 129.48, 129.36, 128.52, 127.42, 124.65, 123.61, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 65.50, 55.97, 53.10, 52.65, 51.00, 37.86, 36.33. ESI-MS: m/z 564.3 ($M + H$)⁺, C₂₉H₂₇F₂N₅O₅ (563.20).

Ethyl (*S*)-2-(4-(3-((3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)carbamoyl)phenyl)-1*H*,1,2,3-triazol-1-yl)acetate (**II-10m**). White solid, yield: 75%, mp: 83–85 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.89 (d, *J* = 7.9 Hz, 1H), 8.63 (s, 1H), 8.34 (d, *J* = 1.9 Hz, 1H), 8.01 (d, *J* = 7.7 Hz, 1H), 7.78 (d, *J* = 7.8 Hz, 1H), 7.56 (t, *J* = 7.7 Hz, 1H), 7.40 (d, *J* = 8.3 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.02 (tt, *J* = 9.4, 2.4 Hz, 1H), 6.65–6.43 (m, 2H), 5.50 (s, 2H), 4.69 (td, *J* = 8.6, 4.6 Hz, 1H), 4.22 (q, *J* = 7.1 Hz, 2H), 3.82 (s, 3H), 3.18 (s, 3H), 3.05–2.93 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 171.29, 167.69, 166.47, 163.76 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.22, 146.32, 143.16 (t, ²*J*_{CF} = 9.1 Hz, 1C), 135.99, 134.77, 131.06, 129.47, 129.36, 128.51, 127.40, 124.64, 123.60, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 62.08, 55.97, 52.65, 51.09, 37.86, 36.34, 14.47. ESI-MS: m/z 578.3 ($M + H$)⁺, C₃₀H₂₉F₂N₅O₅ (577.21).

Methyl (*S*)-4-(3-((3-(3,5-difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)carbamoyl)phenyl)-1*H*,1,2,3-triazol-1-yl)butanoate (**II-10n**). White solid, yield: 67%, mp: 63–65 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.86 (d, *J* = 7.8 Hz, 1H), 8.66 (s, 1H), 8.32 (t, *J* = 1.7 Hz, 1H), 7.99 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.77 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.55 (t, *J* = 7.8 Hz, 1H), 7.41 (d, *J* =

8.4 Hz, 2H), 7.26–7.06 (m, 2H), 7.08–6.95 (m, 1H), 6.61–6.46 (m, 2H), 4.78–4.60 (m, 1H), 4.47 (t, *J* = 7.0 Hz, 2H), 3.82 (s, 3H), 3.59 (s, 3H), 3.18 (s, 3H), 2.99 (td, *J* = 14.1, 9.6 Hz, 2H), 2.39 (t, *J* = 7.3 Hz, 2H), 2.24–2.07 (m, 2H). ¹³C NMR (100 MHz, DMSO) δ 172.98, 171.31, 166.55, 163.76 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.23, 146.31, 143.17 (t, ²*J*_{CF} = 9.1 Hz, 1C), 136.00, 134.74, 131.35, 129.36, 128.45, 127.17, 124.70, 122.24, 115.29, 112.38 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 102.49 (t, ³*J*_{CF} = 25.3 Hz, 1C), 55.97, 52.68, 51.90, 49.26, 37.85, 36.28, 30.60, 25.52. ESI-MS: m/z 592.4 ($M + H$)⁺, C₃₁H₃₁F₂N₅O₅ (591.23).

N-((*S*)-3-(3,5-Difluorophenyl)-1-((4-methoxyphenyl)(methyl)amino)-1-oxopropan-2-yl)-3-(1-(2-(hydroxymethyl)-5-(5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl)tetrahydrofuran-3-yl)-1*H*,1,2,3-triazol-4-yl)benzamide (**II-10o**). White solid, yield: 79%, mp: 142–144 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.40 (s, 1H), 8.88 (d, *J* = 6.5 Hz, 2H), 8.34 (t, *J* = 1.8 Hz, 1H), 8.01 (d, *J* = 7.7 Hz, 1H), 7.91–7.82 (m, 1H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.41 (d, *J* = 8.4 Hz, 2H), 7.09 (d, *J* = 8.4 Hz, 2H), 7.02 (td, *J* = 9.4, 4.7 Hz, 1H), 6.58–6.51 (m, 2H), 6.47 (t, *J* = 6.6 Hz, 1H), 5.45 (dd, *J* = 9.1, 5.0 Hz, 1H), 5.34 (t, *J* = 5.3 Hz, 1H), 4.78–4.51 (m, 1H), 4.30 (q, *J* = 3.9 Hz, 1H), 3.83 (s, 3H), 3.79–3.62 (m, 2H), 3.19 (s, 3H), 2.98 (t, *J* = 7.8 Hz, 2H), 2.78 (dq, *J* = 38.9, 7.0, 6.5 Hz, 2H), 1.83 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ 171.32, 166.54, 164.21 (dd, ¹*J*_{CF} = 246.4 Hz, ³*J*_{CF} = 13.1 Hz, 2C), 159.24, 150.92, 146.52, 142.61 (t, ²*J*_{CF} = 9.1 Hz, 1C), 136.75, 136.00, 134.79, 131.15, 129.37, 128.47, 127.29, 124.82, 121.89, 115.29, 112.37 (dd, ²*J*_{CF} = 19.2 Hz, ⁴*J*_{CF} = 6.1 Hz, 2C), 112.13, 110.13, 102.50 (t, ³*J*_{CF} = 25.3 Hz, 1C), 84.90, 84.33, 61.22, 59.92, 55.98, 52.71, 37.85, 37.59, 36.27, 12.76. ESI-MS: m/z 716.3 ($M + H$)⁺, C₃₆H₃₅F₂N₇O₇ (715.26).

4.1.7. tert-Butyl (*S*)-1-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (12**).** A solution of (*tert*-butoxycarbonyl)-*L*-phenylalanine (**11**, 8.75 mmol, 2.3 g) in 15 mL dichloromethane was added PyBop (10.9 mmol, 5.7 g) at 0 °C, and the mixture stirred for 0.5 h. Subsequently, DIEA (21.87 mmol, 3.61 mL) and 4-methoxy-*N*-methylaniline (7.29 mmol, 1.0 g) were added to the mixture and then stirred at room temperature for another 8–9 h (monitored by TLC). The resulting mixture was evaporated under reduced pressure and the residue was initially washed by 1 N HCl and extracted with ethyl acetate (3 × 20 mL). Then, the combined organic layer was washed with saturated sodium bicarbonate (3 × 50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford corresponding crude intermediate **12** as yellow oil with a yield of 95%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.21 (d, *J* = 8.4 Hz, 3H), 7.15 (d, *J* = 7.1 Hz, 2H), 7.02 (d, *J* = 8.4 Hz, 2H), 6.85–6.75 (m, 2H), 4.15 (q, *J* = 5.4 Hz, 1H), 3.80 (s, 3H), 3.12 (s, 3H), 2.81–2.54 (m, 2H), 1.30 (s, 9H); ¹³C NMR (100 MHz, DMSO) δ 172.21, 158.98, 155.74, 138.53, 136.13, 129.28, 128.47, 126.70, 115.21, 78.33, 55.94, 53.53, 37.86, 37.10, 28.65. ESI-MS: m/z 385.4 ($M + 1$)⁺, C₂₂H₂₈N₂O₄ (384.2).

4.1.8. (*S*)-2-Amino-*N*-(4-methoxyphenyl)-*N*-methyl-3-phenylpropanamide (13**).** Trifluoroacetic acid (34.2 mmol, 5.0 eq.) was added dropwise to intermediate **12** (2.6 g, 6.84 mmol, 1.0 eq.) in 30 mL dichloromethane and stirred at room temperature for 6–7 h. Then, the resulting mixture solution was alkalinized to pH = 9 with saturated sodium bicarbonate solution, and then extracted



with dichloromethane (3 × 20 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to yield the crude product **13** as yellow oil, which was directly injected the next step. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.34–7.15 (m, 3H), 6.90 (s, 6H), 3.77 (s, 3H), 3.35 (t, *J* = 6.9 Hz, 1H), 3.06 (s, 3H), 2.76 (dd, *J* = 12.9, 6.8 Hz, 1H), 2.46 (dd, *J* = 12.9, 7.1 Hz, 1H); ¹³C NMR (100 MHz, DMSO) δ 174.96, 158.76, 139.02, 136.36, 129.51, 128.93, 128.46, 126.54, 115.03, 55.83, 53.38, 42.25, 37.45. ESI-MS: *m/z* 285.3 (M + 1)⁺, C₁₇H₂₀N₂O₂ (284.1).

4.1.9. (S)-3-Ethynyl-N-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide (14). 3-ethynylbenzoic acid (4.22 mmol, 0.62 g) and HATU (5.28 mmol, 2.0 g) were mixed in dichloromethane and stirred in an ice bath for 1 h. Then, the intermediate **13** (6.33 mmol, 1.80 g) and DIEA (7.03 mmol, 1.16 mL) were added to the above solution slowly at 0 °C. The reaction system was then stirred at room temperature for additional 12 h. The solvent was removed under reduced pressure and then 1 N HCl (30 mL) was added, extracted with ethyl acetate (3 × 30 mL). The combined organic layer was washed with saturated sodium bicarbonate (3 × 50 mL). The resulting organic layer was washed with saturated salt water, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford corresponding crude product, which was purified by flash column chromatography to yield compound **14**. Pale yellow solid, mp: 55–57 °C, yield: 87%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (d, *J* = 7.8 Hz, 1H), 7.97 (t, *J* = 1.8 Hz, 1H), 7.83 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.70–7.59 (m, 1H), 7.47 (t, *J* = 7.8 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.16 (qd, *J* = 7.4, 3.5 Hz, 3H), 7.05 (d, *J* = 8.5 Hz, 2H), 6.96–6.77 (m, 2H), 4.66 (q, *J* = 7.3 Hz, 1H), 4.30 (s, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.93 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.75, 165.75, 159.10, 138.56, 136.10, 134.79, 131.01, 129.21, 128.58, 126.82, 122.14, 115.21, 83.31, 81.87, 55.96, 53.11, 37.90, 36.77. ESI-MS: *m/z* 413.00 (M + H)⁺, C₂₆H₂₄N₂O₃ (412.18).

4.1.10. General procedure for the synthesis of target compounds III-15(a–o). The key intermediate **14** (1.0 eq.), azide substituents (1.1 eq.), ascorbic acid sodium (0.6 eq.) and CuSO₄·5H₂O (0.3 eq.) were dissolved in the solution of tetrahydrofuran/water (v : v = 1 : 1). The resulting mixture was stirred at 30–60 °C for 4–6 h. Then the reaction mixture was extracted with ethyl acetate (3 × 10 mL), and the combined organic phase was washed with saturated salt water (3 × 10 mL), dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure to give the corresponding crude target product, which was purified by flash column chromatography to afford product **III-15(a–o)**. Yield: 65–80%.

(S)-N-((1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl))benzamide (III-15a). Yellow solid, yield: 65%, mp: 163–165 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.82 (d, *J* = 7.8 Hz, 1H), 8.66 (s, 1H), 8.31 (t, *J* = 1.7 Hz, 1H), 8.18 (dd, *J* = 8.1, 1.3 Hz, 1H), 8.01 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.87–7.73 (m, 2H), 7.67 (td, *J* = 7.8, 1.4 Hz, 1H), 7.53 (t, *J* = 7.7 Hz, 1H), 7.31 (d, *J* = 8.3 Hz, 2H), 7.24–7.09 (m, 4H), 7.08–7.01 (m, 2H), 6.98–6.82 (m, 2H), 6.06 (s, 2H), 4.67 (q, *J* = 7.3 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.94 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.85, 166.44, 159.09, 148.09, 146.55, 138.58, 136.14, 134.95, 131.11, 130.99, 130.80, 130.22, 129.34, 129.32, 129.27, 128.58, 128.40, 127.48, 126.82, 125.62, 124.88,

123.10, 115.18, 55.95, 53.05, 50.73, 37.90, 36.90. ESI-MS: *m/z* 591.4 (M + H)⁺, C₃₃H₃₀N₆O₅ (590.23).

(S)-N-((1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl))benzamide (III-15b). Yellow solid, yield: 65%, mp: 96–98 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (d, *J* = 7.8 Hz, 1H), 8.75 (s, 1H), 8.31 (dt, *J* = 3.9, 1.7 Hz, 2H), 8.23 (ddd, *J* = 8.3, 2.4, 1.1 Hz, 1H), 7.99 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.80–7.76 (m, 1H), 7.72 (t, *J* = 7.9 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 1H), 7.31 (d, *J* = 8.3 Hz, 2H), 7.21–7.09 (m, 3H), 7.05 (d, *J* = 8.7 Hz, 2H), 6.98–6.85 (m, 2H), 5.87 (s, 2H), 4.67 (q, *J* = 7.3 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.94 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.85, 166.44, 159.08, 148.39, 146.74, 138.58, 138.43, 136.12, 135.25, 134.93, 130.98, 129.34, 129.27, 128.59, 128.37, 127.45, 126.82, 124.85, 123.69, 123.39, 122.65, 115.17, 55.95, 53.06, 52.51, 37.90, 36.86. ESI-MS: *m/z* 591.4 (M + H)⁺, C₃₃H₃₀N₆O₅ (590.23).

(S)-N-((1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl))benzamide (III-15c). Pale yellow solid, yield: 78%, mp: 87–89 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.84 (d, *J* = 7.8 Hz, 1H), 8.75 (s, 1H), 8.33 (d, *J* = 1.7 Hz, 1H), 8.31–8.24 (m, 2H), 8.00 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.78 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.74–7.56 (m, 2H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.24–7.10 (m, 3H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.98–6.87 (m, 2H), 5.89 (s, 2H), 4.67 (q, *J* = 7.3 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.94 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.86, 166.44, 159.08, 147.74, 146.77, 143.81, 138.59, 136.12, 134.93, 130.99, 129.52, 129.34, 129.26, 128.59, 128.38, 127.46, 126.82, 124.86, 124.46, 122.82, 115.17, 55.95, 53.06, 52.65, 37.90, 36.85. ESI-MS: *m/z* 591.4 (M + H)⁺, C₃₃H₃₀N₆O₅ (590.23).

(S)-3-(1-(4-Carbamoylbenzyl)-1H-1,2,3-triazol-4-yl)-N-((1-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl))benzamide (III-15d). White solid, yield: 66%, mp: 96–98 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.81 (d, *J* = 7.8 Hz, 1H), 8.70 (s, 1H), 8.32 (t, *J* = 1.7 Hz, 1H), 8.00 (d, *J* = 7.9 Hz, 2H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.78 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.43 (t, *J* = 6.6 Hz, 3H), 7.31 (d, *J* = 8.3 Hz, 2H), 7.26–7.10 (m, 3H), 7.05 (d, *J* = 8.5 Hz, 2H), 6.99–6.82 (m, 2H), 5.76 (s, 2H), 4.70 (q, *J* = 7.3 Hz, 1H), 3.82 (s, 3H), 3.17 (s, 3H), 2.95 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.87, 167.93, 166.49, 159.09, 146.71, 139.40, 138.55, 136.13, 134.95, 134.60, 131.09, 129.33, 129.28, 128.59, 128.47, 128.20, 127.41, 126.83, 124.84, 122.51, 115.18, 55.94, 53.17, 53.03, 37.91, 36.94. ESI-MS: *m/z* 589.4 (M + H)⁺, C₃₄H₃₂N₆O₄ (588.25).

(S)-N-((1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(2-oxo-2-(phenylamino)ethyl)-1H-1,2,3-triazol-4-yl))benzamide (III-15e). Pale yellow solid, yield: 76%, mp: 105–107 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.56 (s, 1H), 8.85 (d, *J* = 7.8 Hz, 1H), 8.66 (s, 1H), 8.36 (t, *J* = 1.8 Hz, 1H), 8.02 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.78 (dt, *J* = 7.7, 1.4 Hz, 1H), 7.65–7.59 (m, 2H), 7.54 (t, *J* = 7.7 Hz, 1H), 7.34 (q, *J* = 9.5, 8.6 Hz, 4H), 7.21–7.08 (m, 4H), 7.07–7.00 (m, 2H), 6.97–6.88 (m, 2H), 5.44 (s, 2H), 4.69 (q, *J* = 7.3 Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.95 (d, *J* = 7.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO) δ 171.87, 166.43, 164.62, 159.08, 146.20, 138.88, 138.60, 136.13, 134.92, 131.18, 129.41, 129.28, 128.60, 128.32, 127.40, 126.83, 124.70, 124.29, 123.91, 119.71, 115.18, 55.95, 53.05, 52.90, 37.91, 36.90. ESI-MS: *m/z* 589.4 (M + H)⁺, C₃₄H₃₂N₆O₃ (588.25).

(S)-N-((1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(4-sulfamoylbenzyl)-1H-1,2,3-triazol-4-yl))benzamide (III-15f). Pale yellow solid, yield: 61%, mp: 240–242 °C. ¹H NMR (400 MHz,



DMSO- d_6) δ 8.82 (d, $J = 7.8$ Hz, 1H), 8.73 (s, 1H), 8.32 (s, 1H), 8.00 (d, $J = 7.8$ Hz, 1H), 7.86 (d, $J = 8.0$ Hz, 2H), 7.78 (d, $J = 7.9$ Hz, 1H), 7.54 (d, $J = 8.0$ Hz, 3H), 7.40 (s, 2H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.16 (dt, $J = 11.9, 6.7$ Hz, 3H), 7.05 (d, $J = 8.4$ Hz, 2H), 6.98–6.84 (m, 2H), 5.79 (s, 2H), 4.68 (q, $J = 7.3$ Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.85, 166.44, 159.08, 146.73, 144.34, 140.16, 138.57, 136.13, 134.93, 129.34, 129.27, 128.85, 128.38, 127.42, 126.83, 126.65, 124.84, 122.61, 115.18, 55.95, 53.04, 52.94, 37.90, 36.89. ESI-MS: m/z 625.4 ($\text{M} + \text{H}$) $^+$, $\text{C}_{33}\text{H}_{32}\text{N}_6\text{O}_5\text{S}$ (624.22).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(3-phenylpropyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15g**). White solid, yield: 82%, mp: 141–143 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.83 (d, $J = 7.7$ Hz, 1H), 8.68 (s, 1H), 8.33 (t, $J = 1.7$ Hz, 1H), 7.99 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.78 (d, $J = 7.7$ Hz, 1H), 7.53 (t, $J = 7.8$ Hz, 1H), 7.31 (t, $J = 7.6$ Hz, 4H), 7.26–7.22 (m, 2H), 7.19 (d, $J = 10.5$ Hz, 2H), 7.13 (dd, $J = 13.6, 6.7$ Hz, 2H), 7.05 (d, $J = 8.6$ Hz, 2H), 6.95–6.88 (m, 2H), 4.68 (q, $J = 7.4$ Hz, 1H), 4.44 (t, $J = 7.0$ Hz, 2H), 3.82 (s, 3H), 3.16 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H), 2.62 (dd, $J = 8.8, 6.6$ Hz, 2H), 2.29–2.07 (m, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.88, 166.50, 159.09, 146.34, 141.21, 138.61, 136.14, 134.92, 131.36, 129.35, 129.27, 128.87, 128.83, 128.59, 128.31, 127.24, 126.82, 126.49, 124.79, 122.13, 115.18, 55.95, 53.07, 49.61, 37.91, 36.86, 32.37, 31.73. ESI-MS: m/z 574.5 ($\text{M} + \text{H}$) $^+$, $\text{C}_{35}\text{H}_{35}\text{N}_5\text{O}_3$ (573.27).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(3-(thiophen-3-yl)propyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15h**). White solid, yield: 76%, mp: 69–71 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.81 (d, $J = 7.8$ Hz, 1H), 8.57 (s, 1H), 8.29 (s, 1H), 7.95 (d, $J = 7.8$ Hz), 7.77 (d, $J = 7.8$ Hz, 1H), 7.61–7.43 (m, 2H), 7.31 (d, $J = 8.3$ Hz, 2H), 7.24 (d, $J = 2.8$ Hz, 1H), 7.17 (dt, $J = 11.9, 6.7$ Hz, 3H), 7.05 (d, $J = 8.5$ Hz, 2H), 7.01 (d, $J = 4.9$ Hz, 1H), 6.97–6.86 (m, 2H), 4.69 (t, $J = 7.2$ Hz, 3H), 3.83 (s, 3H), 3.27 (t, $J = 7.2$ Hz, 2H), 3.17 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.87, 166.50, 159.09, 146.13, 138.58, 138.26, 136.14, 134.94, 131.30, 129.34, 129.28, 128.69, 128.59, 128.26, 127.24, 126.83, 126.69, 124.73, 122.58, 122.13, 115.18, 55.96, 53.05, 50.55, 37.91, 36.90, 30.69. ESI-MS: m/z 566.4 ($\text{M} + \text{H}$) $^+$, $\text{C}_{32}\text{H}_{31}\text{N}_5\text{O}_3\text{S}$ (565.21).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(quinolin-2-yl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15i**). Pale yellow solid, yield: 81%, mp: 148–150 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 9.60 (s, 1H), 9.55 (d, $J = 2.6$ Hz, 1H), 9.00 (d, $J = 2.5$ Hz, 1H), 8.89 (d, $J = 7.7$ Hz, 1H), 8.48 (t, $J = 1.7$ Hz, 1H), 8.23–8.15 (m, 2H), 8.14–8.08 (m, 1H), 7.95–7.85 (m, 2H), 7.76 (dd, $J = 8.5, 7.0$ Hz, 1H), 7.62 (t, $J = 7.7$ Hz, 1H), 7.33 (d, $J = 8.1$ Hz, 2H), 7.18 (dt, $J = 13.8, 6.8$ Hz, 3H), 7.06 (d, $J = 8.6$ Hz, 2H), 6.99–6.87 (m, 2H), 4.90–4.60 (m, 1H, CHCO), 3.83 (s, 3H, OCH₃), 3.18 (s, 3H, NCH₃), 3.09–2.85 (m, 2H, Ph'-CH₂). ^{13}C NMR (100 MHz, DMSO) δ 171.90, 166.48, 159.11, 147.44, 143.55, 138.58, 136.16, 135.14, 130.98, 130.63, 129.42, 129.35, 129.30, 129.10, 128.61, 127.72, 127.56, 126.84, 126.31, 125.19, 121.02, 115.19, 55.96, 53.13, 37.92, 36.91. ESI-MS: m/z 583.3 ($\text{M} + \text{H}$) $^+$, $\text{C}_{35}\text{H}_{30}\text{N}_6\text{O}_3$ (582.24).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(naphthalen-2-ylmethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15j**). White solid, yield: 71%, mp: 86–88 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.80 (d, $J = 7.8$ Hz, 1H, NH), 8.72 (s, 1H), 8.31 (d, $J = 1.7$ Hz, 1H), 8.08–7.85 (m, 5H), 7.83–7.69 (m, 1H), 7.60–7.45 (m, 4H),

7.30 (d, $J = 8.2$ Hz, 2H), 7.14 (dt, $J = 12.1, 6.7$ Hz, 3H), 7.04 (d, $J = 8.6$ Hz, 2H), 6.97–6.83 (m, 2H), 5.86 (s, 2H), 4.67 (d, $J = 7.4$ Hz, 1H), 3.82 (s, 3H), 3.16 (s, 3H), 2.94 (d, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.84, 166.46, 159.08, 146.68, 138.56, 136.13, 134.93, 133.86, 133.26, 133.03, 131.14, 129.33, 129.27, 129.07, 128.57, 128.32, 128.10, 127.45, 127.37, 127.06, 126.94, 126.80, 126.19, 124.81, 122.44, 115.17, 55.95, 53.77, 53.02, 37.90, 36.90. ESI-MS: m/z 596.4 ($\text{M} + \text{H}$) $^+$, $\text{C}_{37}\text{H}_{33}\text{N}_5\text{O}_3$ (595.26).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(naphthalen-1-ylmethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15k**). White solid, yield: 76%, mp: 109–111 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.79 (d, $J = 7.8$ Hz, 1H), 8.62 (s, 1H), 8.33–8.17 (m, 2H), 8.10–7.94 (m, 3H), 7.74 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.66–7.41 (m, 5H), 7.30 (d, $J = 8.3$ Hz, 2H), 7.21–7.07 (m, 3H), 7.04 (d, $J = 8.8$ Hz, 2H), 6.97–6.85 (m, 2H), 6.18 (s, 2H), 4.66 (d, $J = 7.3$ Hz, 1H), 3.82 (s, 3H), 3.15 (s, 3H), 2.93 (d, $J = 7.3$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.83, 166.46, 159.07, 146.53, 138.56, 136.13, 134.92, 133.88, 131.78, 131.14, 131.04, 129.61, 129.33, 129.26, 129.18, 128.57, 128.33, 127.90, 127.33, 126.80, 126.68, 126.10, 124.79, 123.69, 122.40, 115.17, 55.94, 53.02, 51.61, 37.89, 36.89. ESI-MS: m/z 596.4 ($\text{M} + \text{H}$) $^+$, $\text{C}_{37}\text{H}_{33}\text{N}_5\text{O}_3$ (595.26).

(*S*)-*N*-(1-((4-Methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-3-(1-(naphthalen-1-ylmethyl)-1*H*-1,2,3-triazol-4-yl)benzamide (**III-15l**). White solid, yield: 63%, mp: 71–73 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.84 (d, $J = 7.8$ Hz, 1H), 8.62 (s, 1H), 8.33 (t, $J = 1.8$ Hz, 1H), 8.00 (d, $J = 7.7$ Hz, 1H), 7.78 (d, $J = 7.8$ Hz, 1H), 7.54 (t, $J = 7.7$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.16 (dt, $J = 13.5, 6.8$ Hz, 3H), 7.05 (d, $J = 8.5$ Hz, 2H), 6.98–6.78 (m, 2H), 5.52 (s, 2H), 4.68 (d, $J = 7.4$ Hz, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 3.16 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 171.85, 168.17, 166.41, 159.09, 146.39, 138.59, 136.14, 134.96, 130.97, 129.35, 129.28, 128.60, 128.36, 127.51, 126.83, 124.76, 123.59, 115.19, 55.95, 53.10, 53.04, 51.00, 37.91, 36.92. ESI-MS: m/z 528.3 ($\text{M} + \text{H}$) $^+$, $\text{C}_{29}\text{H}_{29}\text{N}_5\text{O}_5$ (527.22).

Methyl (*S*)-2-(4-(3-((1-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)phenyl)-1*H*-1,2,3-triazol-1-yl)acetate (**III-15m**). Pale yellow solid, yield: 73%, mp: 87–89 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.85 (d, $J = 7.8$ Hz, 1H), 8.62 (s, 1H), 8.33 (d, $J = 1.8$ Hz, 1H), 8.00 (d, $J = 7.7$ Hz, 1H), 7.78 (d, $J = 7.8$ Hz, 1H), 7.54 (t, $J = 7.7$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.16 (dt, $J = 13.6, 6.8$ Hz, 3H), 7.08–7.00 (m, 2H), 6.98–6.79 (m, 2H), 5.50 (s, 2H), 4.68 (q, $J = 7.3$ Hz, 1H), 4.22 (q, $J = 7.1$ Hz, 2H), 3.82 (s, 3H), 3.16 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H), 1.25 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, DMSO) δ 171.85, 167.70, 166.41, 159.09, 146.37, 138.59, 136.14, 134.96, 130.99, 129.35, 128.60, 128.36, 127.50, 126.82, 124.75, 123.59, 115.18, 62.08, 55.95, 53.04, 51.09, 37.91, 36.91, 14.47. ESI-MS: m/z 542.4 ($\text{M} + \text{H}$) $^+$, $\text{C}_{30}\text{H}_{31}\text{N}_5\text{O}_5$ (541.23).

Ethyl (*S*)-2-(4-(3-((1-((4-methoxyphenyl)(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)phenyl)-1*H*-1,2,3-triazol-1-yl)acetate (**III-15n**). Pale yellow solid, yield: 68%, mp: 116–118 °C. ^1H NMR (400 MHz, DMSO- d_6) δ 8.83 (d, $J = 7.8$ Hz, 1H), 8.65 (s, 1H), 8.32 (t, $J = 1.7$ Hz, 1H), 7.98 (d, $J = 7.7$ Hz, 1H), 7.78 (d, $J = 7.7$ Hz, 1H), 7.53 (t, $J = 7.7$ Hz, 1H), 7.32 (d, $J = 8.2$ Hz, 2H), 7.16 (dt, $J = 13.1, 6.8$ Hz, 3H), 7.09–7.01 (m, 2H), 6.98–6.85 (m, 2H), 4.68 (q, $J = 7.4$ Hz, 1H), 4.47 (t, $J = 6.9$ Hz, 2H), 3.82 (s, 3H, OCH₃), 3.59 (s, 3H), 3.17 (s, 3H), 2.95 (d, $J = 7.2$ Hz, 2H), 2.39 (t, $J = 7.3$ Hz, 2H), 2.15 (p, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, DMSO) δ 172.99, 171.88, 166.50, 159.08, 146.35, 138.60, 136.13, 131.29, 129.35,



129.27, 128.59, 128.31, 127.27, 126.83, 124.78, 122.23, 115.17, 55.95, 53.07, 51.90, 49.26, 37.90, 36.86, 30.61, 25.53. ESI-MS: m/z 556.3 (M + H)⁺, C₃₁H₃₃N₅O₅ (555.25).

3-(1-(2-(Hydroxymethyl)-5-(5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)-N-((S)-1-(4-methoxyphenyl)(methylamino)-1-oxo-3-phenylpropan-2-yl)benzamide (**III-150**). White solid, yield: 74%, mp: 132–134 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.39 (s, 1H), 8.99–8.71 (m, 2H), 8.33 (t, *J* = 1.7 Hz, 1H), 8.00 (d, *J* = 7.7 Hz, 1H), 7.85 (d, *J* = 1.4 Hz, 1H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.54 (t, *J* = 7.8 Hz, 1H), 7.32 (d, *J* = 8.3 Hz, 2H), 7.16 (dt, *J* = 12.9, 6.7 Hz, 3H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.99–6.87 (m, 2H), 6.47 (t, *J* = 6.6 Hz, 1H), 5.44 (dt, *J* = 8.8, 5.4 Hz, 1H), 5.33 (t, *J* = 5.3 Hz, 1H), 4.67 (q, *J* = 7.4 Hz, 1H), 4.30 (q, *J* = 3.9 Hz, 1H), 3.82 (s, 3H), 3.76–3.55 (m, 2H), 3.16 (s, 3H), 2.95 (d, *J* = 7.3 Hz, 2H), 2.88–2.61 (m, 2H), 1.83 (d, *J* = 1.1 Hz, 3H). ¹³C NMR (100 MHz, DMSO) δ 171.87, 166.47, 164.21, 159.09, 150.92, 146.56, 138.60, 136.74, 136.14, 134.97, 131.08, 129.35, 128.60, 127.39, 126.83, 124.89, 121.89, 115.18, 110.13, 84.90, 84.35, 61.23, 59.93, 55.96, 53.09, 37.91, 37.59, 36.84, 12.75. ESI-MS: m/z 680.3 (M + H)⁺, C₃₆H₃₇N₇O₇ (679.28).

4.2. In vitro anti-HIV assay

4.2.1. Assessment of inhibitory activity on HIV-1 replication in TZM-bl cells. Inhibitory activity of compounds against HIV-1 infection in TZM-bl cells was measured as the reduction in luciferase gene expression after multiple rounds of virus infection of the cells similar to that described previously.³⁷ Briefly, 200 TCID₅₀ of virus (NL₄₋₃) was used to infect TZM-bl cells in the presence of various concentrations of compounds. Two days after infection, the culture medium was removed from each well and 100 μL of Bright Glo reagent (Promega, Luis Obispo, CA) was added to the cells for measurement of luminescence using a Victor 2 luminometer. The effective concentration (EC₅₀) against HIV-1 strains was defined as the concentration that caused a 50% reduction of luciferase activity (Relative Light Units) compared to virus control wells.

4.2.2. Cytotoxicity assay. A CytoTox-Glo cytotoxicity assay (Promega) was used to determine the cytotoxicity of the synthesized compounds. Parallel to the antiviral assays, TZM-bl cells were cultured in the presence of various concentrations of the compounds for 1 day. The percent of viable cells was determined by following the protocol provided by the manufacturer. The 50% cytotoxic concentration (CC₅₀) was defined as the concentration that caused a 50% reduction in cell viability.

4.3. Binding to CA proteins analysis via surface plasmon resonance (SPR)

All binding assays were performed on a ProteOn XPR36 SPR Protein Interaction Array System (Bio-Rad Laboratories, Hercules, CA). The instrument temperature was set at 25 °C for all kinetic analyses. ProteOn GLH sensor chips were preconditioned with two short pulses each (10 s) of 50 mM NaOH, 100 mM HCl, and 0.5% sodium dodecyl sulfide. Then the system was equilibrated with PBS-T buffer (20 mM sodium phosphate, 150 mM NaCl, and 0.005% polysorbate 20, pH 7.4). The surface of a GLH sensor chip was activated

with a 1 : 100 dilution of a 1 : 1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.2 M) and sulfo-*N*-hydroxysuccinimide (0.05 M). Immediately after chip activation, the HIV-1 NL4-3 capsid protein constructs, purified as in Xu *et al.*,²⁶ were immobilized on the sensor chip surface. The capsid monomer was prepared at a concentration of 0.1 mg L⁻¹ in 10 mM sodium acetate, pH 5.0 and injected across ligand flow channels for 13 min at a flow rate of 25 μL min⁻¹. The capsid disulfide stabilized hexamer was prepared at a concentration of 0.05 mg mL⁻¹ in 10 mM sodium acetate, pH 5.0 and injected across ligand flow channels for 50 s at a flow rate of 30 μL min⁻¹. Then, after unreacted protein had been washed out, excess active ester groups on the sensor surface were capped by a 5 min injection of 1 M ethanolamine HCl (pH 8.0) at a flow rate of 30 μL min⁻¹. A reference surface was similarly created by immobilizing a non-specific protein (IgG b12 anti HIV-1 gp120; was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (IgG1 b12) from Dr Dennis Burton and Carlos Barbas) and was used as a background to correct non-specific binding.

To prepare a compound for direct binding analysis, compound stock solutions, along with 100% DMSO, and totaling 30 μL was made to a final volume of 1 mL by addition of sample preparation buffer (PBST, pH 7.4). Preparation of analyte in this manner ensured that the concentration of DMSO was matched with that of running buffer with 3% DMSO. Serial dilutions were then prepared in the running buffer (PBS, 3% DMSO, 0.005% polysorbate 20, pH 7.4) and injected at a flow rate of 100 μL min⁻¹, for a 1 min association phase, followed by up to a 5 min dissociation phase using the “one-shot kinetics” capability of the Proteon instrument.³⁸ Data were analyzed using the ProteOn Manager Software version 3.0 (Bio-Rad). The responses from the reference flow cell were subtracted to account for the nonspecific binding and injection artifacts. The equilibrium dissociation constant (*K*_D) for the interactions, and derived from a minimum of three experiments, were calculated in ProteOn Manager Version 3.1.0.6 (Bio-Rad, Hercules, CA), using the equilibrium analysis function.

4.4. Molecular dynamics simulation

4.4.1. Initial structure preparation. The initial X-ray structure of hexameric HIV-1 CA was downloaded from the protein databank (PDB code 5HGL with a resolution of 3.1 Å).³⁹ Only one monomer of the hexameric structure was used for the entire MD study. This structure, which is used in the binding assay, has four mutated amino acids (M185A, E45C, A14C and W184A). 5HGL structure misses amino acids Ala-88, Gly-89, Pro-90, Ile-91, Ala-92, Pro-93, Gly-94, Gln-95, Lys-182, Asn-183, Ala-184, and Ala-185. Accordingly, we used HIV-1 CA X-ray structure 3GV2 to extract the missed amino acids with their corresponding tertiary structure and add them to 5HGL structure after their alignment using discovery studio software.⁴⁰ Then, the whole system was energy minimized to remove any strains



due to the added amino acid residues, which is then used for further study.

4.4.2. Molecular dynamics simulation production. Atomic point charges for **II-10c** were derived from AM1-BCC charge model with ANTECHAMBER module of AMBER14. Coordinate and topology parameters were prepared using ff14sb force field for HIV-1 CA monomer and GAFF force field for **II-10c**. The whole system was solvated in explicit water TIP3PBOX octahedral solvent box model with 9 Å cut, and the system was neutralized by Nat ions. Water was minimized for 10 000 cycles using steepest descent and then conjugate gradient algorithms. The whole system was then minimized for 5000 cycles using steepest descent followed by conjugate gradient algorithms. Then, water was equilibrated for 20 ps at constant volume and periodic boundaries with weak strength restraints on the whole system through the equilibrium stage, a force constant of 10 Å as position restraint. The whole system was then equilibrated for 40 ps using constant pressure periodic boundaries with no restraints. The minimized and equilibrated structure was used in the molecular dynamics simulation for 1 ms at constant temperature (300 K) and constant pressure (1 atm). Non-bonded forces were calculated at a cutoff distance of 10 Å. H Mass Repartition was used to shift the mass of all hydrogen atoms of solute to 3.024 Da.⁴¹ This allowed us to use an integration time step of 4 fs during MD.⁴¹ SHAKE bond length constraint involving hydrogen atoms was turned on.

4.4.3. Clustering. All frames were imaged and then water molecules and Nat ions were stripped off. All frames were aligned against the first frame of the MD production using protein residues only. They were then clustered by DBSCAN algorithm⁴² implemented in CPPTRAJ of AMBER14 on **II-10c** using minimum points of 3 and epsilon of 2.5 with no frame orientation (no fit), which clustered all frames according to **II-10c** to explore the binding site of 5HGL.

4.5. Cell permeability assay

Caco-2 cells purchased from ATCC were seeded onto polyethylene membranes (PET) in 96-well BD Insert plates at 1×10^5 cells per cm^2 , and refreshed medium every 4–5 days until to the 21st to 28th day for confluent cell monolayer formation. The transport buffer in the study was HBSS with 10 mM HEPES at $\text{pH } 7.40 \pm 0.05$. Test compound were tested at 2 μM in A to B direction in duplicate, control compounds nadolol, metoprolol were tested at 2 μM in A to B direction in duplicate. Final DMSO concentration was adjusted to less than 1%. The plate was incubated for 2 hours in CO_2 incubator at 37 ± 1 °C, with 5% CO_2 at saturated humidity without shaking. And all samples after mixed with acetonitrile containing internal standard were centrifuged at 4000 rpm for 10 min. Subsequently, 100 μL supernatant solution was diluted with 100 μL distilled water for LC/MS/MS analysis. Concentrations of test and control compounds in starting solution, donor solution, and receiver solution were quantified by LC/MS/MS methodologies, using peak area ratio of analyte/internal standard. After transport assay, lucifer yellow rejection assay was applied to determine the Caco-2 cell monolayer integrity.

The apparent permeability coefficient P_{app} (cm s^{-1}) was calculated using the equation:

$$P_{\text{app}} = (dC_r/dt) \times V_r / (A \times C_0)$$

where dC_r/dt is the cumulative concentration of compound in the receiver chamber as a function of time ($\mu\text{M s}^{-1}$); V_r is the solution volume in the receiver chamber (0.075 mL on the apical side, 0.25 mL on the basolateral side); A is the surface area for the transport, *i.e.* 0.0804 cm^2 for the area of the monolayer; C_0 is the initial concentration in the donor chamber (μM).

Percent recovery was calculated using the equation:

$$\% \text{ Solution recovery} = 100 \times [(V_r \times C_r) + (V_d \times C_d)] / (V_d \times C_0)$$

where V_d is the volume in the donor chambers (0.075 mL on the apical side, 0.25 mL on the basolateral side); C_d and C_r are the final concentrations of transport compound in donor and receiver chambers, respectively. C_c is the compound concentration in the cell lysate solution (μM). V_c is the volume of insert well (0.075 mL in this assay).

4.6. Measurements of water solubility and log P

Water solubility was measured in water at pH 7.0 and phosphate buffer at pH 7.4 and 2.0 using an HPLC-UV method. Compounds were initially dissolved in DMSO at 10 mg mL^{-1} 10 μL of this stock solution was spiked into purified water (1 mL) with the final DMSO concentration being 1%. The mixture was ultrasonic for 2 h at room temperature and restored at room temperature overnight. The saturated solution was filtrated through a filter membrane (pore size = 0.22 μm) and transferred to other Eppendorf tubes for analysis by HPLC-UV. The sample was performed in duplicate. For quantification, a model LC-20AT HPLC-UV (SHIMADZU) system was used with an Inertsil® OD-SP-C18 column (150 mm \times 4.6 mm, 5 μm) and MeOH/water as eluant. The flow rate was 1.0 mL min^{-1} , and the injection volume was 20 μL . Aqueous concentration was determined by comparison of the peak area of the saturated solution with a standard curve plotted peak area *versus* known concentrations, which were prepared by solutions in MeOH at 80, 40, 20, 10, 5, and 2.5 $\mu\text{g mL}^{-1}$.

DMSO stock solution 1 mg mL^{-1} was prepared, and then, 20 μL of this solution was added into *n*-octanol (1 mL) and H_2O (1 mL). The mixture was ultrasonic for 2 h at room temperature and left to sit overnight. Each solution (~ 0.4 mL) was transferred from two phases, respectively, into other Eppendorf tubes for HPLC analysis. The instrument and conditions were the same as those for solubility determination. The P (partition coefficient) value was calculated by the peak area ratios in *n*-octanol and in H_2O .

Conflicts of interest

The authors declare no competing financial interest.



Acknowledgements

Financial support from the National Natural Science Foundation of China (NSFC No. 81273354, 81573347), Key Project of NSFC for International Cooperation (No. 81420108027), Young Scholars Program of Shandong University (YSPSDU, No. 2016WLJH32), the Fundamental Research Funds of Shandong University (No. 2017JC006), Key Research and Development Project of Shandong Province (No. 2017CXGC1401), Major Project of Science and Technology of Shandong Province (No. 2015ZDJS04001), NIH R01GM125396 (Cocklin, PI) and NIH T32-MH079785 are gratefully acknowledged.

References

- 1 E. L. Asahchop, M. A. Wainberg, R. D. Sloan and C. L. Tremblay, *Antimicrob. Agents Chemother.*, 2012, **56**, 5000–5008.
- 2 P. Zhan, C. Pannecouque, E. De Clercq and X. Liu, *J. Med. Chem.*, 2016, **59**, 2849–2878.
- 3 L. Menendez-Arias, *Antiviral Res.*, 2013, **98**, 93–120.
- 4 X. F. Zuo, Z. P. Huo, D. W. Kang, G. C. Wu, Z. X. Zhou, X. Y. Liu and P. Zhan, *Expert Opin. Ther. Pat.*, 2018, **28**, 299–316.
- 5 Y. N. Song, P. Zhan, X. Li, D. Rai, E. De Clercq and X. Y. Liu, *Curr. Med. Chem.*, 2013, **20**, 815–832.
- 6 S. Thenin-Houssier and S. T. Valente, *Curr. HIV Res.*, 2016, **14**, 270–282.
- 7 G. C. Wu, W. A. Zalloum, M. E. Meuser, L. L. Jing, D. W. Kang, C. H. Chen, Y. Tian, F. F. Zhang, S. Cocklin, K. H. Lee, X. Y. Liu and P. Zhan, *Eur. J. Med. Chem.*, 2018, **158**, 478–492.
- 8 M. Yamashita and A. N. Engelman, *Trends Microbiol.*, 2017, **25**, 741–755.
- 9 T. Schaller, K. E. Ocwieja, J. Rasaiyaah, A. J. Price, T. L. Brady, S. L. Roth, S. Hue, A. J. Fletcher, K. Lee, V. N. KewalRamani, M. Noursadeghi, R. G. Jenner, L. C. James, F. D. Bushman and G. J. Towers, *PLoS Pathog.*, 2011, **7**, e1002439.
- 10 E. M. Campbell and T. J. Hope, *Nat. Rev. Microbiol.*, 2015, **13**, 471–483.
- 11 V. Le Sage, A. J. Mouland and F. Valiente-Echeverria, *Virus Res.*, 2014, **193**, 116–129.
- 12 A. N. Engelman and P. K. Singh, *Cell. Mol. Life Sci.*, 2018, **75**, 2491–2507.
- 13 C. S. Lopez, J. D. Eccles, A. Still, R. E. Sloan, R. L. Barklis, S. M. Tsagli and E. Barklis, *Virology*, 2011, **417**, 137–146.
- 14 W. S. Blair, C. Pickford, S. L. Irving, D. G. Brown, M. Anderson, R. Bazin, J. A. Cao, G. Ciaramella, J. Isaacson, L. Jackson, R. Hunt, A. Kjerrstrom, J. A. Nieman, A. K. Patick, M. Perros, A. D. Scott, K. Whitby, H. Wu and S. L. Butler, *PLoS Pathog.*, 2010, **6**, e1001220.
- 15 S. K. Carnes, J. H. Sheehan and C. Aiken, *Curr. Opin. HIV AIDS*, 2018, **13**, 359–365.
- 16 A. Saito, D. Ferhadian, G. A. Sowd, E. Serrao, J. Shi, U. D. Halambage, S. Teng, J. Soto, M. A. Siddiqui, A. N. Engelman, C. Aiken and M. Yamashita, *J. Virol.*, 2016, **90**, 5808–5823.
- 17 J. Zhou, A. J. Price, U. D. Halambage, L. C. James and C. Aiken, *J. Virol.*, 2015, **89**, 9068–9079.
- 18 A. J. Price, D. A. Jacques, W. A. McEwan, A. J. Fletcher, S. Essig, J. W. Chin, U. D. Halambage, C. Aiken and L. C. James, *PLoS Pathog.*, 2014, **10**, e1004459.
- 19 B. K. Ganser-Pornillos, A. Cheng and M. Yeager, *Cell*, 2007, **131**, 70–79.
- 20 A. Bhattacharya, S. L. Alam, T. Fricke, K. Zdrozny, J. Sedzicki, A. B. Taylor, B. Demeler, O. Pornillos, B. K. Ganser-Pornillos, F. Diaz-Griffero, D. N. Ivanov and M. Yeager, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 18625–18630.
- 21 A. T. Gres, K. A. Kirby, V. N. KewalRamani, J. J. Tanner, O. Pornillos and S. G. Sarafianos, *Science*, 2015, **349**, 99–103.
- 22 J. Shi, J. Zhou, V. B. Shah, C. Aiken and K. Whitby, *J. Virol.*, 2011, **85**, 542–549.
- 23 H. Z. Xu, T. Franks, G. Gibson, K. Huber, N. Rahm, C. S. De Castillia, J. Luban, C. Aiken, S. Watkins, N. Sluis-Cremer and Z. Ambrose, *Retrovirology*, 2013, **10**, 70.
- 24 A. L. Brass, D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J. Xavier, J. Lieberman and S. J. Elledge, *Science*, 2008, **319**, 921–926.
- 25 R. Konig, Y. Y. Zhou, D. Elleder, T. L. Diamond, G. M. C. Bonamy, J. T. Irelan, C. Y. Chiang, B. P. Tu, P. D. De Jesus, C. E. Lilley, S. Seidel, A. M. Opaluch, J. S. Caldwell, M. D. Weitzman, K. L. Kuhen, S. Bandyopadhyay, T. Ideker, A. P. Orth, L. J. Miraglia, F. D. Bushman, J. A. Young and S. K. Chanda, *Cell*, 2008, **135**, 49–60.
- 26 J. P. Xu, A. C. Francis, M. E. Meuser, M. Mankowski, R. G. Ptak, A. A. Rashad, G. B. Melikyan and S. Cocklin, *J. Drug Des. Res.*, 2018, **5**, 1070.
- 27 J. P. Xu, J. D. Branson, R. Lawrence and S. Cocklin, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 824–828.
- 28 P. Gao, L. Sun, J. S. Zhou, X. Li, P. Zhan and X. Y. Liu, *Expert Opin. Drug Discovery*, 2016, **11**, 857–871.
- 29 G. C. Wu, Y. Gao, D. W. Kang, B. S. Huang, Z. P. Huo, H. Q. Liu, V. Poongavanam, P. Zhan and X. Y. Liu, *MedChemComm*, 2018, **9**, 149–159.
- 30 X. Jiang, X. Hao, L. Jing, G. Wu, D. Kang, X. Liu and P. Zhan, *Expert Opin. Drug Discovery*, 2019, 1–11.
- 31 Z. X. Zhou, T. Liu, G. C. Wu, D. W. Kang, Z. P. Fu, Z. Wang, E. De Clercq, C. Pannecouque, P. Zhan and X. Y. Liu, *Org. Biomol. Chem.*, 2019, **17**, 3202–3217.
- 32 Y. Tian, Z. Q. Liu, J. H. Liu, B. S. Huang, D. W. Kang, H. Zhang, E. De Clercq, D. Daelemans, C. Pannecouque, K. H. Lee, C. H. Chen, P. Zhan and X. Y. Liu, *Eur. J. Med. Chem.*, 2018, **151**, 339–350.
- 33 X. S. Wang, B. S. Huang, X. Y. Liu and P. Zhan, *Drug Discovery Today*, 2016, **21**, 118–132.
- 34 G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell and A. J. Olson, *J. Comput. Chem.*, 2009, **30**, 2785–2791.
- 35 X. Jiang, J. Yu, Z. Zhou, J. Kongsted, Y. Song, C. Pannecouque, E. Clercq, D. Kang, V. Poongavanam,



- X. Liu and P. Zhan, *Med. Res. Rev.*, 2019, DOI: 10.1002/med.21581.
- 36 G. Wu, T. Zhao, D. Kang, J. Zhang, Y. Song, V. Namasivayam, J. Kongsted, C. Pannecouque, E. De Clercq, V. Poongavanam, X. Liu and P. Zhan, *J. Med. Chem.*, 2019, DOI: 10.1021/acs.jmedchem.9b00359.
- 37 Z. Dang, W. H. Lai, K. D. Qian, P. Ho, K. H. Lee, C. H. Chen and L. Huang, *J. Med. Chem.*, 2009, **52**, 7887–7891.
- 38 T. Bravman, V. Bronner, K. Lavie, A. Notcovich, G. A. Papalia and D. G. Myszka, *Anal. Biochem.*, 2006, **358**, 281–288.
- 39 D. A. Jacques, W. A. McEwan, L. Hilditch, A. J. Price, G. J. Towers and L. C. James, *Nature*, 2016, **536**, 349–353.
- 40 P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson and M. T. Stahl, *J. Chem. Inf. Model.*, 2010, **50**, 572–584.
- 41 C. W. Hopkins, S. Le Grand, R. C. Walker and A. E. Roitberg, *J. Chem. Theory Comput.*, 2015, **11**, 1864–1874.
- 42 J. Y. Shao, S. W. Tanner, N. Thompson and T. E. Cheatham, *J. Chem. Theory Comput.*, 2007, **3**, 2312–2334.

